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Mitochondrial uncoupling proteins (UCPs) are anion / solute transporters that 
dissipate the proton gradient used to drive ATP generation. By allowing protons to flow 
down their electrochemical gradient, UCP activation releases the energy generated from 
mitochondrial substrate oxidation as heat. This thermogenic process is important in 
normal thermoregulation (i.e. non-shivering thermogenesis), and also serves as an 
attractive target in the treatment of obesity by lowering metabolic efficiency. 
The skeletal muscle (SKM) enriched UCP homologue, UCP3, is associated with 
increased energy expenditure, fatty acid metabolism, and insulin sensitivity. Unlike the 
cold-induced prototypical pathway of UCP1-mediated non-shivering thermogenesis in 
brown adipose tissue (BAT), the mechanisms underlying the thermogenic actions of 
UCP3 in SKM are not well characterized. Although global UCP3 knockout mice exhibit 
normal thermoregulatory responses to cold under fed conditions, they exhibit an 
attenuated hyperthermic response when administered amphetamine-type drugs. In our 
initial investigation, we show that selective overexpression of UCP3 in SKM by the 





hyperthermia in the UCP3-/- background (TgSKM UCP3-/-), but not in the UCP1/UCP3 
double knockout background (TgSKM UCP1-/-+UCP3-/-). Taken together, these findings 
further bolster the role of UCP3 as a thermogenic mediator in SKM, and suggest a novel 
mechanism of crosstalk between BAT UCP1 and SKM UCP3 in Meth-induced 
hyperthermia. 
In the second aspect of my project, we characterized the underlying mechanisms 
of UCP3-dependent thermogenesis within SKM by utilizing an immunoprecipitation- 
based mass spectrometry approach to identify interacting partners of UCP3. These 
analyses corroborated previous work performed by our lab, and demonstrated that UCP3 
interacts with a subset of fatty acid metabolizing enzymes. Interestingly, one such 
enzyme, enoyl-CoA hydratase-1 (ECH1), is involved in the metabolism of oleic acid, a 
known ligand activator of UCP3. This work reveals that  ECH1:UCP3  complex 
formation enhances uncoupled-respiration and fatty acid metabolism, and that genetic 
mouse models in vivo show that UCP3 and ECH1 participate in a common pathway of 
thermogenesis. These findings support a new model by which UCP3-dependent 
thermogenesis in SKM is mediated in part through its cooperation with ECH1, and 
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1Chapter 1: Introduction 
 
1.1 Background: Cellular bioenergetics and thermogenesis in the treatment of 
obesity 
  Obesity is a complex disease that develops when energy intake exceeds energy 
expenditure.  This energy imbalance leads to an excess accumulation of body fat or 
adiposity, which is associated with many devastating medical complications including 
type 2 diabetes mellitus, metabolic syndrome, cardiovascular disease, Alzheimer’s, and 
even some type of cancers (Haslam & W. P. T. James 2005).  According to the CDC, 
more than 34.9% of US adults are classified as obese with a body mass index (BMI) >30 
(Ogden et al. 2014).   
 Current therapies primarily focus on reducing caloric intake to oppose the energy 
imbalance that causes obesity.  Apart from maintaining a healthy diet and increasing 
physical activity, the available clinical approaches to treat obesity are risky and/or 
relatively ineffective in terms of long-term weight loss (Melnikova & Wages 2006).  This 
includes invasive bariatric surgical procedures, and a select few FDA approved drugs that 
are associated with devastating side effects for the patient. Therefore, it is essential to 
                                                
1 Portions of this chapter are adopted from:  
 
Dao, C.K., Nowinski, S.M. & Mills, E.M., 2014. The heat is on: Molecular mechanisms of drug-induced 
hyperthermia. Temperature, 1(3), pp.183–191.  
 




develop new obesity therapies that can lower toxicity in patients and also have a more 
substantial effect on weight loss in the long-term.  
  An attractive alternative approach to treat obesity is through targeting cellular 
bioenergetics to increase energy expenditure.  On a molecular level, cellular 
bioenergetics, in large part, occurs in the mitochondria where the oxidation of nutrients 
through the tricarboxylic acid (TCA) cycle and electron transport chain (ETC) is coupled 
to ATP production (i.e. oxidative phosphorylation).  More specifically, intermediates 
from the TCA cycle contribute electrons to the ETC, which causes complexes of the ETC 
to pump protons from the mitochondrial matrix into the intermembrane space.  This 
generates an electrochemical gradient that is used to drive ATP synthesis by allowing 
protons to flow back down the gradient through F1/F0-ATP synthase  (F1/F0-ATPase).  
 Although oxidative phosphorylation is a tightly coupled process, chemical energy 
conversion is an inefficient process by nature, where some energy is inherently lost as 
heat.  Indeed, in mammalian systems there are many examples of specific physiologically 
uncoupled or “futile cycling” processes that are energy consuming and thermogenic.  The 
idea of utilizing these thermogenic processes to lower metabolic efficiency and increase 
energy expenditure as a means to combat obesity, originates from research regarding 
inducible proton leak mediated by uncoupling protein 1 (UCP1) in brown adipose tissue 
(BAT) (Feldmann et al. 2009).  UCP1 is expressed on the inner mitochondrial membrane 
and has the ability to uncouple oxidative phosphorylation by allowing protons to leak 
back into the mitochondrial matrix.  As protons flow down their concentration gradient 
and circumvent F1/F0-ATP synthase, the energy used to fuel ATP generation is released 
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in the form of heat.  This mechanism is the basis of a process known as adaptive non-
shivering thermogenesis that occurs generally in BAT of rodents and newborn babies, 
where heat is generated in response to cold in order to maintain core body temperature 
(Cannon et al. 1982; Cannon & Nedergaard 2004).  
 The use of uncoupling to increase energy expenditure and achieve weight loss has 
already been demonstrated with the clinical use of the non-selective uncoupler of 
oxidative phosphorylation known as 2,4-dinotrophenol, starting back in the 1930’s.  
Although effective in weight loss, the drug has a narrow therapeutic window and can 
have toxic side effects including hyperthermia, tachycardia, diaphoresis, tachypnea, and 
even death (Grundlingh et al. 2011).   
 Uncoupling-dependent non-shivering thermogenesis in the treatment of obesity 
and –related metabolic diseases has gained attention over the past decade with the 
discovery that adult humans possess greater amounts of BAT depots than originally 
postulated (Nedergaard et al. 2007).  Importantly, it has also been shown that in addition 
to BAT, non-shivering thermogenesis can also occur in skeletal muscle tissues (SKM).  
However, our understanding of the mechanisms that regulate the complex interplay 
between mitochondrial uncoupling and energy balance are still unclear.  Regardless, 
these new findings highlight the potential opportunities in targeting cellular bioenergetics 
through uncoupling in BAT and SKM.  Our work provides valuable insight into the 
mechanisms that regulate non-shivering thermogenesis that will likely be relevant in 
developing novel strategies to combat the energetic imbalance seen with obesity by 
lowering metabolic efficiency.   
 
 4 
1.2 Bioenergetics and metabolism 
 Normal energy metabolism is driven by the oxidation of three principle substrates 
derived from nutrients- glucose, fatty acids, and amino acids.  These substrates can be  
 
 
Illustration 1.1 Normal cellular bioenergetics  
The catabolism of glucose, fatty acids, and branched chain amino acids (BCAA) all 
generate acetyl-CoA, which fuels the tricarboxylic acid cycle (TCA).  The TCA cycle 
produces the reducing equivalents, NADH and FADH2, which provide electrons to the 
electron transport chain (ETC).  As the electrons flow through the complexes, protons are 
pumped in to the intermembrane space of the mitochondria.  The resulting proton 
gradient is coupled to F1/F0 ATP synthase (ATPase) to generate the high-energy 




taken up exogenously from diet, or can be released from intracellular stores that involve 
catabolic processes such as glycolysis, lipolysis, and proteolysis (amino acid catabolism). 
Distinct metabolic pathways in the mitochondria metabolize the different fuel substrates, 
however these processes all converge with the formation of acetyl-CoA, a key substrate 
that is fed into the TCA cycle (Illustration 1.1).  Each turn of the TCA cycle generates 
reduced coenzyme equivalents (NADH and FADH2) that deliver electrons to the ETC 
and fuels ATP generation through oxidative phosphorylation.  Ultimately, all cells rely 
heavily on these metabolic processes to meet their energetic needs.  
 
1.2.1 Glucose metabolism  
Carbohydrates and sugars, such as glucose, serve as an important energy fuel 
source for cells.  In healthy individuals, whole body glucose homeostasis is maintained 
through 4 key metabolic processes: glycolysis, glycogen synthesis, glycogenolysis, and 
gluconeogenesis.  It is important to note that depending on the tissue type, the interplay 
between these metabolic processes in maintaining glucose homeostasis can vary.  For 
example, in a fasted state the rates of glycolysis in the liver decreases and the glucose 
stored in the liver via gluconeogenesis and glycogen synthesis is released into the 
bloodstream to be delivered to brain and SKM (Guo et al. 2012).  Here, we will focus 
mainly on glucose metabolism in SKM, as it is a principle tissue-site of glucose uptake, 
and accounts for up to 70-80% of glucose disposal in humans administered a 





Illustration 1.2 Insulin-stimulated glucose uptake and metabolism in SKM  
Insulin binds to the insulin receptor and initiates a signaling cascade that stimulates 
GLUT4 translocation to the cell membrane through exocytosis.  Glucose is taken up into 
the cell through the GLUT4 transporter and can either be stored as glycogen or be further 
degraded through glycolysis.  The 10 enzymatic reactions of glycolysis result in the net 
generation of 2 molecules of pyruvate, ATP, and the reducing equivalent NADH.  In 
anaerobic conditions, pyruvate can be converted to lactate by lactate dehydrogenase 
(LDH).  In aerobic conditions, the mitochondrial pyruvate dehydrogenase complex 
(PDH) catalyzes oxidative decarboxylation of pyruvate to acetyl-CoA, which is 
subsequently fed into the TCA cycle to generate the reducing equivalents (NADH2 and 
FADH) which fuel ATP generation through the electron transport chain.   
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Glucose uptake into SKM is facilitated by specific members of the glucose transporter 
family (GLUTS), GLUT1 and GLUT4.  While GLUT1 mediates constitutive and basal 
glucose uptake in cells, GLUT4- dependent glucose transport is stimulated by insulin 
(Larance et al. 2008).  In an absorptive state right after a meal, the spike in plasma 
glucose concentration stimulates insulin release from the pancreatic β-cells, which leads 
to an increase in SKM glucose uptake and inhibition of fatty acid oxidation (Randle et al. 
1963).  Insulin stimulates translocation of the GLUT4 receptor to the plasma membrane 
through exocytosis (Rea & D. E. James 1997).  Glucose is transported into the cell via 
GLUT4, and is then phosphorylated by hexokinase (HK) to produce glucose-6-phosphate 
(G6P).  At this point in the glycolytic pathway, G6P can either be stored as glycogen or 
undergo further degradation through a series of glycolytic reactions in the cytoplasm that 
results in the generation of two molecules of pyruvate and a net of two molecules of ATP 
(Illustration 1.2).  It has been reported that about 30-40% of glucose is oxidized while 
approximately 15% is stored as glycogen following an oral glucose tolerance test (Kelley 
et al. 1988).    
The metabolic fate of pyruvate generated from glycolysis varies with anaerobic 
and aerobic conditions.  For example, in fast twitch-glycolytic muscle fibers that have a 
low oxidative capacity and contain low levels of the oxygen binding protein, myogoblin, 
pyruvate can be rapidly metabolized by lactate dehydrogenase (LDH) to generate and 
release lactate into circulation (Kruszynska et al. 2001).  However, in highly oxidative 
muscle fibers, pyruvate is taken up into mitochondria, and is subsequently metabolized 
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by pyruvate dehydrogenase (PDH) to generate acetyl- CoA, a principal substrate that 
feeds into the TCA cycle.  
1.2.2 Fatty acid oxidation  
 Fatty acids serve as another important metabolic fuel source, especially for tissues 
with high energetic requirements including heart, liver, BAT, and SKM.  Fatty acid 
metabolism becomes particularly important in certain physiological contexts such as 
fasting (i.e. hypoglycemia), hyperthermia/heat-related illness, and metabolic stress. 
 Fatty acids can be released into circulation through hydrolysis/lipolysis of 
triglyceride stores by hormone-sensitive lipase (HSL).  Once liberated, fatty acids are 
bound to albumin for transport in the blood stream to surrounding tissues, and into cells 
through membrane-associated proteins, including fatty acid translocase (FAT/CD36) or 
plasmalemmal fatty acid-binding protein (FABPpm) (van der Vusse et al. 2002).  Once 
inside the cell, the fatty acids are bound to cytoplasmic fatty acid-binding proteins 
(FABPs), and then further modified by fatty acyl Coenzyme A synthetases (FACs) for 
uptake into certain intracellular organelles.  Before fatty acids can be taken up they must 
be conjugated to a molecule of coenzyme A, forming fatty acyl-CoA.  Most fatty acyl-
CoAs are then transported into either peroxisomes or mitochondria through two distinct 
uptake mechanisms mediated through ATP-binding cassette transporters or carnitine 
transporters, respectively. Both peroxisomes and mitochondria possess the machinery to 
perform fatty acid oxidation aka β-oxidation, however it has been reported that a majority 





Illustration 1.3 Carnitine transport cycle in mitochondria 
When fatty acid metabolism is favored (e.g. fasting) fatty acyl-CoA molecules are 
transported in the mitochondrial matrix via the carnitine transport cycle.  This specific 
carrier system consists of three enzymes- carnitine palmitoyltransferase I (CPTI) , 
carnitine-acylcarnitine translocase (CACT), and carnitine palmitoyltransferase I (CPTII).  
CPTI, located on the outer mitochondrial membrane, catalyzes the rate-limiting step of 
this transport system and replaces the coenzymeA moiety (SCOA) with carnitine.  In the 
final step, the fatty acyl-carnitine is converted back into fatty acyl-CoA by CPTII, which 
is located on the inner face of the inner mitochondrial membrane.  The resulting fatty 
acyl-CoA enters the β-oxidation spiral and generates one molecule of acetyl-CoA that is 
subsequently fed into the TCA cycle.  The reduced cofactors produced from the TCA 
cycle and the β-oxidation fuel ATP generation through the electron transport chain.  
R Carnitine
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While, mitochondrial β-oxidation is closely associated with energy production through 
oxidative phosphorylation, peroxisomal β-oxidation is thought to be more involved in the 
degradation of complex fatty acid species, such as branched chain fatty acids or very long 
chain fatty acids(Kunau et al. 1995).  Therefore, initial processing of complex fatty acids 
through peroxisome β-oxidation gives rise to medium chain fatty acids that can then be 
transported to mitochondria for complete oxidation (Borgne & Demarquoy 2012). 
 Unlike peroxisomal uptake of fatty acids mediated through an ATP-binding 
cassette transporters (van Roermund et al. 2011), the transport of the fatty acyl-CoA 
metabolites into mitochondria requires the carnitine shuttle system.  The outer 
mitochondrial membrane is impermeable to fatty acyl-CoA esters.  The first reaction of 
the shuttle system (rate-limiting step) is catalyzed by carnitine palmitoyltransferase 1 
(CPT1), on the outer mitochondrial membrane (Kopec & Fritz 1971).  Before the fatty 
acyl-CoA is allowed to transverse the membrane, CPT1 converts fatty acyl-CoA into 
acylcarnitine.  Once in the intermembrane space, the acyl-carnitine is shuttled by 
carnitine-acylcarnitine translocase (CACT) into the mitochondrial matrix where the 
carnitine moiety is replaced with CoA by CPT2.  The resulting mitochondrial acyl-CoA 
molecule undergoes a series of enzymatic reactions, collectively known as β-oxidation, 
resulting in the formation of acetyl-CoA that can be fed into the TCA cycle (Illustration 







Illustration 1.4 The β-oxidation spiral  
The catabolism of fatty acyl-CoA molecules through β-oxidation leads to the generation 
of acetyl-CoA, NADH, and FADH2..  There are 4 enzymes involved in β-oxidation: acyl-
CoA dehydrogenase, enoyl-CoA hydratase, hydroxy acyl-CoA dehydrogenase, and 
ketoacyl-CoA thiolase.  In the final step of β-oxidation, ketoacyl-CoA thiolase links a 
coenzymeA moiety to the third carbon in the fattty acid chain, resulting in the formation 
of one molecule of fatty acyl-CoA and acetyl-CoA.  The resulting fatty acyl-CoA (now 


































1.2.2.1 Mitochondrial β-oxidation of saturated fatty acids 
 β-oxidation involves a series of 4 enzymatic reactions that act in a repetitive cycle 
catalyzed by acyl-CoA dehydrogenase, enoyl-CoA hydratase, hydroxyacyl-CoA 
dehydrogenase, and ketoacyl-CoA thiolase.  It is important to note that multiple forms of 
these enzymes with the same mechanistic properties exist, but differ based on their 
localization and specificity for substrates of different fatty acid chain lengths (Kunau et 
al. 1995).  Although the functional and physiological organization of these enzymes in 
the mitochondria remains unclear, it has been proposed that these β-oxidation enzymes 
organize as large multienzyme complexes to channel substrates from one enzyme to 
another.  Existing as an organized enzyme complex, rather than free floating enzymes, 
would provide a clear kinetic advantage and would explain the observed struggle in 
detecting intermediates of β-oxidation(Liang et al. 2001; Sumegi et al. 1991).   
 With each turn of the β-oxidation cycle one molecule of NADH, FADH2, and 
acetyl-CoA is generated, and the fatty acyl-CoA chain is shortened by two carbons 
(Illustration 1.4).  This cycle continues until the fatty acid chain is completely degraded 
to acetyl-CoA.  The fatty acid chains containing an odd-number of carbons are degraded 
to the three-carbon molecule propionyl-CoA, which can then be converted to succinyl-
CoA and fed directly into the TCA cycle (Schulz 2002).   
1.2.2.2 Unsaturated fatty acid metabolism 
 The presence of cis double bonds along the carbon chain of (poly)unsaturated 
fatty acids prevents the complete degradation of these species through normal β-
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oxidation.  Indeed, unsaturated fatty acid metabolism requires a set of auxiliary enzymes 
to act on these pre-existing double bonds before they can enter the β-oxidation spiral 
(Stoffel & Caesar 1965).  Depending on the placement of the double bond(s) along the 
fatty acid chain, either in an odd-numbered or even-numbered position(s), unsaturated 
fatty acids can be metabolized by different pathways (Illustration 1.5).   
 Even-numbered double bonds can be metabolized by the collective actions of two 
enzymes, the NADPH-dependent 2,4-dienoyl-CoA reductase (DECR) and Δ3,Δ2-enoyl-
CoA isomerase (ECI) enzymes before entering the β-oxidation spiral.  In contrast, the 
degradation of unsaturated fatty acids with double bonds in odd-numbered positions (e.g. 
oleic and linoleic acid) is more complex and can be potentially metabolized by either the 
classic isomerase-dependent or reductase-dependent pathway.  Kinetic studies to 
characterize the relative contribution of these two pathways in oleic acid metabolism r 
and revealed that the isomerase dependent pathway accounted for more than 80% of the 
total flux (Shoukry & Schulz 1998).  Despite the relatively small contribution of the 
reductase-dependent pathway, it is still regarded as an essential component in the 
degradation of unsaturated fatty acids with double bonds in odd-numbered positions.   It 
has been proposed that the absence of the reductase-dependent pathway would lead to the 
accumulation of the 3-trans, 5-cis-dienoyl-CoA intermediate (Schulz & Kunau 1987)  
that  is exclusively metabolized by the enzyme, Δ3,5, Δ2,4-dienoyl-CoA isomerase/enoyl-





Illustration 1.5 Degradation of different types of unsaturated fatty acids 
Saturated fatty acids can be completely degraded through traditional β-oxidation.  
Unsaturated fatty acids with double bonds on even numbered carbons along the fatty acid 
chain (e.g. linoleic acid) must be converted to a trans-2, enoyl-CoA ester by acyl-CoA 
dehydrogenase (AD), dienoyl-CoA reductase (DECR) and enoyl-CoA isomerase (ECI) 
before being degraded through β-oxidation.  Unsaturated fatty acids with double bonds 
on odd numbered carbons (e.g. oleic acid) are converted to the trans-2,cis-4-dienoyl-CoA 
ester by AD before being metabolized to the trans-2-enoyl-CoA intermediate either 
through the isomerase dependent pathway or the reductase dependent pathway.  Enoyl-
CoA hydratase (EH); hyoxyacyl-CoA dehydrogenase (HD); Keto-thiolase (KT); Enoyl-








































































1.2.3 Oxidative phosphorylation 
  The degradation of glucose, amino acids, and fatty acids (i.e. unsaturated and 
saturated) all lead to the formation of acetyl-CoA, a principle substrate in the TCA cycle.  
When acetyl-CoA enters the TCA cycle it is combined with oxaloacetate to form citrate, 
which then undergoes a series of oxidizing reactions that ultimately lead to the 
regeneration of oxaloacetate to restart the cycle.  Each turn of the cycle generates two 
molecules of CO2 and one molecule of GTP, as well as the reduced cofactors, NADH and 
FADH2 that subsequently contribute their electrons to the ETC.   
The ETC is located on the inner mitochondrial membrane and consists of protein 
complexes that serve as electron donors and acceptors.  NADH delivers electrons to 
complex I (NADH dehydrogenase) while FADH2 donates electrons to complex II 
(succinate dehydrogenase) of the ETC.  The electrons can flow from either complex I or 
II to the Q cycle  (coenzyme Q), which then delivers electrons to complex III 
(cytochrome c oxidoreductase).  Interestingly, electrons can also be fed directly into the 
Q cycle via FAD-linked proteins including electron transferring flavoprotein 
dehydrogenase (ETF) and glycerol-3-phosphate dehydrogenase (G3PDH) (Fisher-
Wellman & Neufer 2012).  Electrons from the Q cycle then flow from complex III to 
complex VI (cytochrome c oxidase) via cytochrome c (cyt c).  In the final step of the 
ETC, molecular oxygen is reduced to H2O (oxygen consumption).  As electrons flow 
through the ETC, the complexes use the energy released from each redox reaction to 
pump protons (H+) from the matrix into the intermembrane space.  This establishes an 





Illustration 1.6 The electron transport chain and oxidative phosphorylation 
The TCA cycle generates the reducing equivalents, NADH and FADH2 which provide 
electrons (e-) to complex I and II located on the inner mitochondrial membrane, 
respectively.  Within the electron transport chain (ETC), e- flow through complex I and II 
to the ubiquinone cycle (Q).  FADH2 generated from the degradation of fatty acids 
through β-oxidation can be directly fed into the Q cycle via electron transferring 
flavoprotein dehydrogenase  (ETF).  From the Q cycle, e- are passed to complex III, 
cytochrome C (Cyt C), complex IV, and the final acceptor, molecular oxygen (O2) to 
form water.  As e- flow through the complexes, protons are pumped into the 
intermembrane space by complexes I, III, and IV, resulting in an electrochemical 
gradient.  The proton motive force generated by the electrochemical gradient is used to 





 and generate ATP through F1/F0 ATPase (complex V of the ETC), a process known as 
oxidative phosphorylation.   For the most part, the ETC is coupled to oxidative 
phosphorylation and the only way for flux through ETC to continue is if energy from the 
electrochemical gradient is dissipated.  In other words, if the rate of proton re-entry into 
the matrix slows down, this change will be accompanied by a corresponding alteration in 
electron flow, O2 consumption, and ATP generation.  Therefore, assessing the ratio 
between the respiration rates before and after ADP addition, i.e. respiratory control ratio, 
is considered an excellent measure of mitochondrial dysfunction in isolated mitochondria 
(Brand & Nicholls 2011).  Another excellent measure of mitochondrial dysfunction is the 
excess generation of reactive oxygen species (ROS), which is also implicated in the  
etiology of diseases including diabetes, cancer, and inflammatory disorders (Sena & 
Chandel 2012).  ROS generation is a natural byproduct of mitochondrial metabolism that 
occurs as membrane potential (ΔΨ) builds across the inner mitochondrial membrane, thus 
creating a ‘back pressure’ that opposes proton pumping in the intermembrane space and 
slows electron flow through the ETC.  This negative pressure can cause electrons to slip 
from the complexes and react with molecular oxygen to form superoxide and other ROS 
species.  ROS generation can play a diverse role in normal cellular physiology function 
as key signaling molecules, however excess ROS production can lead to oxidative stress 
and damage.  Given this dichotomy, in healthy cells mitochondrial ROS generation is 
regulated through antioxidant systems that mitigate ROS production (Sheu et al. 2006) to 
maintain energy and redox balance. 
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1.3 Basal metabolic rate and thermogenesis 
 The majority of the energy obtained from nutrient uptake is used to meet the 
energetic demands of an organism, or is converted to thermal energy.  By nature, cellular 
metabolism has low thermodynamic efficiency where energy can be lost as heat (Silva 
2011).  Obligatory thermogenesis or basal metabolic rate (BMR) is the rate of energy 
utilized to perform basic life functions in a resting state at thermoneutrality.  It can also 
be viewed as the constitutive heat production of an organism and major determinant in 
“setting” core body temperature i.e. basal thermogenesis.  
 Unlike poikilotherms, homeotherms have the ability to maintain core body 
temperature within a narrow range.  For example, in response to severe cold temperatures 
where obligatory thermogenesis is unable to defend core body temperature, the body can 
activate mechanisms of heat production and conservation (i.e. cutaneous vasoconstriction 
and piloerection).  The physiological heat-generating processes involved in maintaining 
core body temperature (shivering and non-shivering thermogenesis) are collectively 
referred to as facultative thermogenesis (Silva 2006).  
1.3.1 Thermoregulation 
At thermoneutrality, the temperature at which animals are not required to generate 
“extra” body heat to maintain normal body temperature, basal core temperature is 
maintained by heat generated from the combined inefficiency of all cellular and bodily 
metabolic reactions (i.e. obligatory thermogenesis, BMR).  By contrast, in response to 
diverse stimuli including chronic cold exposure, endotherms have the ability to rapidly 
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generate heat in order to maintain core body temperature through adaptive facultative 
thermogenesis.  The hypothalamus is commonly referred to as the master controller of 
thermoregulation (Charkoudian 2003) and coordinates the central and peripheral 
neurochemical mechanisms that regulate thermogenesis and heat dissipation.  In response 
to elevated temperatures, the hypothalamus can activate heat dissipating mechanisms 
through sympathetic signaling to increase cutaneous vasodilation and sweating (in 
humans) (Nielsen 1998).  Similarly, when mammals are faced with acute cold exposure, 
hypothalamic activation of the SNS initially inhibits heat dissipation through cutaneous 
vasoconstriction, and stimulates shivering thermogenesis in skeletal muscle (SKM) where 
muscle activity is increased to generate heat (De Witte 2002).  However, shivering 
thermogenesis is energetically inefficient and impractical to sustain for longer periods of 
time.  Therefore, endotherms have evolved other mechanisms of heat generation that are 
recruited to withstand chronic cold exposure without shivering (Silva 2006), i.e. non-
shivering thermogenesis (Table 1.1).  These thermogenic processes can also be induced 
by certain pharmacological agents (Rusyniak & Sprague 2006).  
1.3.1.1 Fever versus toxicant-induced hyperthermia 
A variety of pharmacological and toxicological agents can trigger a thermogenic 
response by altering hypothalamic and sympathetic nervous system (SNS) regulation of 
body temperature (i.e. toxicant-induced hyperthermia).  The most well characterized 
toxicant-induced hyperthermic syndromes include neuroleptic malignant syndrome, 





Table 1.1 Categories of thermogenesis 
The energy obtained from nutrient intake is used for key metabolic processes or lost in 
the generation.  Different categories of thermogenesis are classified based on their 
function/component and sites of heat production.  Obligatory thermogenesis contributes 
to an organism’s standard metabolic rate and refers to the heat generated from all 
processes required to maintain a basal state.  Facultative thermogenesis refers to 
regulated-heat production in response to environmental changes or diet.  Cold 
temperatures can activate systems of shivering and non-shivering thermogenesis as part 
of an adaptive response to maintain core body temperature.  Pharmacological agents that 
interfere with mechanisms of normal thermoregulation can activate different components 
of facultative thermogenesis and lead to toxicant-induced hyperthermia.   
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hyperthermia.  These conditions are associated with devastating medical complications 
including hyperkalemia, renal failure, metabolic acidosis, liver failure, rhabdomyolysis 
(Chan et al. 1997; Olson & Benowitz 1984), and even death.   
It is important to distinguish between fever and drug-induced hyperthermia.  Even 
though both conditions result in elevated core body temperatures, the underlying 
mechanisms are distinct.  Fever is a regulated process that presents as a physiological 
response to infection when the hypothalamus increases the body’s “set point” (Stitt 
1979).  In drug-induced hyperthermia, hypothalamic control is compromised and the 
body is pushed into a hypermetabolic state where excessive heat production cannot be 
mitigated by normal autoregulatory mechanisms of temperature control (Chan et al. 
1997).  Therefore, the use of antipyretics including acetaminophen and salicylates are 
ineffective in treating drug-induced hyperthermia where the implicating mechanisms 
stem from hypothalamic dysregulation (Stitt 1979; Chan et al. 1997).  The only available 
treatments of drug-induced hyperthermia focus on alleviating the severity and duration of 
the hyperthermia through supportive care methods including rehydration and external 
cooling (Chan et al. 1997; Musselman & Saely 2013).  
 
1.3.2 Facultative thermogenesis  
Facultative thermogenesis occurs primarily in BAT and SKM, and can be 
classified into two categories, shivering and non-shivering thermogenesis.  The initial 
response to cold temperatures is to increase muscle activity through shivering 
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thermogenesis in order to generate heat.  However, prolonged exposure to cold 
temperatures requires the activation of adaptive non-shivering thermogenesis.  SNS 
activation of BAT mitochondrial uncoupling protein 1 (UCP1) is the prototypical 
mechanism of nonshivering thermo.  UCP1 (originally identified as thermogenin) was 
initially characterized as a thermogenic regulator back in the 1980’s (Lin & Klingenberg 
1980) and belongs to a family of highly conserved mitochondrial solute carriers that have 
the ability to increase mitochondrial respiration and uncouple oxidative phosphorylation 
from ATP production.  By allowing protons to leak back into the matrix and circumvent 
the F1/F0-ATPase complex of the ETC, UCP1 converts the energy stored in the 
electrochemical gradient to thermal energy (released as heat).   
UCP-mediated proton leak is a biochemical futile cycle where two metabolic 
processes are “uncoupled, and thus energy consuming. From an evolutionary standpoint, 
the existence of these uncoupled/futile cycling systems can be kinetically advantageous 
in severe situations that require rapid energy release (Rolfe & Brown 1997).  
Sarcoplasmic reticulum calcium extrusion and ATP dependent calcium uptake in SKM is 
another futile cycle that is implicated in adaptive non-shivering thermogenesis (Bal et al. 
2012) as well as drug-induced hyperthermia (Rusyniak & Sprague 2006; Dao et al. 
2014). Other examples of futile cycles include the actin-myosin cycling in SKM 
contraction, leakage of the sodium-potassium ATPase pump, and triglyceride/fatty acid 
cycling (Rolfe & Brown 1997) (She et al. 2007).  
 Although, research towards the clinical uses of BAT has been reinvigorated with 
the discovery that adult humans have more BAT than originally postulated (Nedergaard 
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et al. 2007; Cypess et al. 2009), the extent to which BAT contributes to non-shivering 
thermogenesis in adult humans remains unclear (Heaton 1972). Compared to rodents and 
newborns, adult humans possess minimal amounts of BAT.  Therefore it is likely that 
alternative mechanisms of non-shivering thermogenesis, independent of BAT, have 
evolved.  Indeed, animals that lack BAT (amphibians, reptiles, and birds) still exhibit 
SNS-dependent thermogenesis (Hissa et al. 1975; Harri & Hedenstam 1972; Barre & 
Rouanet 1983).  
Skeletal muscle (SKM) is an attractive site of non-shivering thermogenesis due to 
its sheer size and the fact that it is a highly metabolic tissue in the body.  As mentioned 
earlier, SKM is also the primary site of shivering thermogenesis, another subcategory of 
facultative thermogenesis.  However, the mechanisms involved in muscle non-shivering 
thermogenesis are far less well characterized compared to BAT.  Several studies have 
implied that thermogenic systems similarly designed to SNS regulation of UCP1-
mediated proton leak in BAT may also exist in SKM (Silva 2011; Block & Franzini-
Armstrong 1988; Bal et al. 2012).  This idea is supported by studies that show NE 
administration can increase metabolism and thermogenesis in isolated muscle systems 
(Mejsnar & Jansky 1971).  In addition to this, work elegantly done by Astrup and 
colleagues has demonstrated that ephedrine-induced thermogenesis is mainly derived 
from SKM in adult humans (Astrup et al. 1985; Astrup et al. 1984).  Furthermore, most if 
not all types of drug-induced hyperthermic conditions are associated with SKM damage 
(Rusyniak & Sprague 2006).  For example, malignant hyperthermia (MH) involves a 
well-defined mechanism of drug-induced hyperthermia in susceptible populations that 
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carry mutations in the SKM ryanodine receptor calcium channel (RYR1).  In response to 
inhalational anesthetics, these mutations can alter Ca2+ leakage in SKM and lead to 
uncontrolled hyperthermia by allowing Ca2+ to pass down its concentration gradient, thus 
uncoupling the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase pump (SERCA) from 
ATP hydrolysis (Bal et al. 2012). Although it is not established whether RYR1 is a direct 
regulator of non-shivering thermogenesis under normal, physiological circumstances, it is 
likely that SKM intra-myocyte calcium handling, in general, plays an important role in 
adaptive non-shivering thermogenesis. This idea is corroborated with recent studies 
showing that mice lacking sarcolipin, a negative regulator of SERCA were unable to 
defend core body temperature in cold environments (Bal et al. 2012).  
1.4 Metabolic derangements in obesity-induced insulin resistance 
Recent research regarding the governing mechanisms of obesity-induced insulin 
resistance focuses heavily on the interplay between mitochondrial bioenergetics and fatty 
acid metabolism.  Although there is a clear association between ectopic fat accumulation 
and the development of insulin resistance in SKM, the underlying mechanisms at a 
molecular level remain a matter of controversy.  The two prominent theories that have 
emerged to explain obesity-induced insulin resistance in SKM both center on 
mitochondrial dysfunction.  The first theory is based on a series of clinical studies that 
showed fatty acid metabolism and overall SKM mitochondrial oxidative capacity was 
severely diminished in severely obese or insulin resistant settings (Morino et al. 2006; 
Petersen et al. 2003; Petersen et al. 2004; J. Y. Kim et al. 2000).  These observations led 
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to a proposed model of fatty acid-induced insulin resistance where deficiencies in 
mitochondrial oxidative function and fatty acid metabolism lead to the accumulation of 
diacylglycerol and other toxic lipid intermediates that antagonize insulin signaling 
(Roden et al. 1996).  This model is attractive in that it implies that increasing 
mitochondrial fatty acid oxidation would improve insulin sensitivity.  
In recent years another model of obesity-induced insulin resistance has gained 
momentum and centers on the principles of mitochondrial bioenergetics to explain that 
the observed mitochondrial deficiencies seen with insulin resistance are actually a 
consequence of fuel supply exceeding energy demand.  This model is based on the 
premise that oxidative phosphorylation is governed by energy demand/expenditure, and 
is thus rarely operating at maximal capacity.  Therefore, enhancing fatty acid oxidation 
alone without a corresponding increase in energy expenditure/demand will impinge 
persistent pressure on mitochondrial respiration and function, thus leading to an 
impairment of insulin signaling pathways.  This model is supported by the observation 
that despite an up-regulation of key fatty acid metabolizing enzymes in response to high 
fat diet, fatty acid intermediates still accumulate due to the energetic imbalance where 
supply exceeds energy expenditure (Koves et al. 2008; Turner et al. 2007).  Furthermore, 
studies in different animal and human models of obesity-induced insulin resistance have 
shown that administration of pharmacological drugs that inhibit CPT1, a master regulator 
of mitochondrial β-oxidation, can improve glucose homeostasis (Deems et al. 1998; 
Barnett et al. 1992).   
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Another relevant topic regarding the underlying mechanisms of mitochondrial 
overload in obesity-induced insulin resistance is the generation of reactive oxygen 
species.  ROS generation can greatly antagonize mitochondrial function and induce 
oxidative stress, but can also serve as potent activators of several stress-responsive 
kinases that impair insulin signaling in SKM, including c-jun amino-terminal kinases 
(JNK), IκB kinase catalytic subunit β (IKK-β), and protein kinase C (PKC) (S. 
Chakraborti & T. Chakraborti 1998).  In understanding how excess metabolic fuel can 
have detrimental effects on mitochondrial respiration it is important to remember that 
proton conductance governs electron flow which is determined by the demand of the 
reducing equivalents (NADH and FADH2) that are generated through substrate uptake 
and subsequent metabolism.  Therefore, the accumulation of excess reducing equivalents 
due to chronic over nutrition will impose additional pressure at the entry point of the 
electron transport chain into complex I (NADH) and/or the ubiquinone cycle (FADH2).  
Furthermore, it has also been shown that the relative proportion of electrons that feed into 
complex I, or the ubiquinone cycle can also affect redox balance.  For example, the 
oxidation of saturated fatty acid palmitate feeds electrons directly into the ubiquinone 
cycle via ETF, and is associated with higher rates of H2O2 generation (St-Pierre et al. 
2002; Seifert et al. 2010).  Regardless, the chronic pressure on the electron transport 
chain alters mitchondrial redox balance and creates a microenvironment that is highly 
susceptible to the generation of reactive oxygen species (Fisher-Wellman & Neufer 
2012).  This model is supported by studies that show genetic and pharmacologic 
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interventions that mitigate mitochondria oxidative stress can improve insulin signaling 
and glucose homeostasis (Henriksen 2006; Houstis et al. 2006).  
Although chronic overnutrition can trigger a complex series of metabolic events 
that contribute to obesity-induced insulin resistances, a clear approach to target all these 
metabolic derangements is to increase energy expenditure/demand. As mentioned earlier 
in the preceding sections, increasing the rate of substrate oxidation alone, more 
specifically β-oxidation, without a corresponding elevation in energy demand can further 
exacerbate the problem of mitochondrial overload on the electron transport chain.  
However, if the flux through β-oxidation increases as a consequence of added demand, 
this metabolic shift complies with the principles of mitochondrial bioenergetics that are 
governed by energy demand/expenditure.  Thus, our current understanding of 
mitochondrial bioenergetics and obesity-induced insulin resistance suggests the key to 
developing treatments with long-term efficacy involve new strategies that attack the root 
cause of the problem and promote energy inefficiency.   
1.5 The mitochondrial uncoupling protein family 
 Research regarding the clinical use of uncoupling proteins (UCPs) in the 
treatment of obesity and -related metabolic disorders have been prominent since their 
initial characterization in the late 1970s (Brand & Esteves 2005).   Mitochondrial UCPs 
are nuclear encoded members of the mitochondrial solute carrier (SLC) family that have 
the ability to lower mitochondrial membrane potential through proton leak.  Five UCP 





Illustration 1.7 Futile proton cycling through mitochondrial uncoupling proteins 
Mitochondrial Uncoupling Proteins (UCPs) are members of the mitochondrial solute 
carrier family (SLC) family that have the ability to uncouple the electron transport chain 
from ATP production.  By allowing protons to flow down (H+) gradient and circumvent 
F1/F0ATP synthase (F1/F0ATPase), UCPs promote inefficient energy utilization and 
increase mitochondrial respiration.  Therefore, cells have to increase flux through the 
catabolic pathways that feed into the TCA cycle in order to replenish the reducing 






Table 1.2 Uncoupling proteins counteract the metabolic derangements seen with 
obesity-related complications 
The metabolic effects of mitochondrial uncoupling on fatty acid oxidation, reactive 
oxygen species (ROS) production, energy metabolism directly oppose the metabolic 
phenotypes seen with obesity-related pathologies.  Through uncoupling of the electron 
transport chain and ATP generation, these proteins can drive substrate oxidation and 
relieve pressure on the electron transport chain to lower ROS production by counteracting 





“canonical” UCP member.  While UCP1 is exclusively expressed in BAT, the tissue 
distribution of the other UCP homologues is more diverse.  Compared to UCP4 and 
UCP5, UCP2 and UCP3 share high sequence homology with UCP1 (Krauss et al. 2005). 
Interestingly, all members of the UCP family have been described in diverse roles related 
to metabolism, however their physiological relevance is still under investigation (Krauss 
et al. 2005).     
 The effects of UCP activity on mitochondrial bioenergetics directly opposes the 
energetic and physiological abnormalities seen in obesity and –related metabolic 
disorders (Table 1.2).  True to their name, UCPs have the ability to uncouple nutrient 
oxidation from ATP synthesis by dissipating the proton gradient.  UCP-regulated proton 
leak decreases the efficiency of oxidative phosphorylation, which results in a 
compensatory increase in substrate oxidation and flux through the ETC by mitochondria 
in order to maintain membrane potential and ATP production.  In conjunction with 
increasing flux and lowering the proton motive force, UCPs can relieve the reducing 
pressure on the ETC from nutrient overload and mitigate ROS production (Esteves & 
Brand 2005).  
1.5.1 The canonical uncoupling protein  
UCP1, also referred to as thermogenin, constitutes a significant portion (~10%) of 
the mitochondrial membrane protein in BAT (Rousset et al. 2004). In the canonical 





Illustration 1.8 Cold-induced non-shivering thermogenesis in BAT 
Adaptive non-shivering thermogenesis is an evolutionary process that occurs through 
UCP1 expression in brown adipose tissue of small rodents and newborn babies. In 
response to cold, rodents and newborns are able to maintain their body temperature when 
norepinephrine (NE) is released to activate the cyclicAMP-protein kinase A-hormone 
sensitive lipase (cAMP-PKA-HSL) pathway which leads to the lipolysis of triglycerides 
and the release of fatty acids.  This event is critical in thermogenic function as the fatty 
acids play an important role in activating UCP1 and serve as a combustive fuel source for 






norepinephrine (NE) from sympathetic neurons that densely innervate BAT tissue depots 
(R. E. Smith & Horwitz 1969).  NE binds to β3-adrenoreceptors (β3AR) on brown 
adipocytes, initiating a signaling cascade that leads to the generation of free fatty acids  
from cytoplasmic multilocular lipid droplets via the cyclic AMP-protein kinase A-
hormone sensitive lipase signaling pathway (cAMP-PKA-HSL) (Nicholls & Locke 
1984a; Jezek & Freisleben 1994).  Free fatty acids are then transported into BAT 
mitochondria via the carnitine shuttle system, where they are used as fuel substrates for 
β-oxidation, and activate UCP1-mediated thermogenesis (Cannon & Nedergaard 2004). 
An interesting characteristic of UCP1-dependent non-shivering thermogenesis in 
response to cold is its regulation through fatty acids, as well as its inhibition by purine 
nucleotides (ATP or GDP).  The physiological importance of fatty acids in stimulating 
non-shivering thermogenesis is reinforced by  
studies demonstrating that thermogenesis is severely impaired in mice with genetic 
defects in enzymes that affect fatty acid metabolism and transport (Guerra et al. 1998). 
Likewise, studies that show fatty acids alone can simulate NE-induced thermogenesis in 
the presence of UCP1 (Nahrendorf et al. 2000), and that BAT thermogenesis can be 
blocked through inhibition of lipolysis (Fredriksson et al. 2001), further supports  the role 
of lipolysis in β3AR –stimulation of UCP1-dependent thermogenesis.  With regard to the 
direct molecular mechanisms underlying fatty activation of UCP1-mediated proton leak, 
recent work utilizing a patch clamp method to measure UCP1 currents has demonstrated 
that UCP1 doesn’t possess constitutive activity (most likely inhibited by purine 
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nucleotides) until activated by long chain fatty acids.  Once activated, UCP1 acts as long 
chain fatty acid anion / H+ symporter to mediate proton leak across the inner 
mitochondrial membrane (Fedorenko et al. 2012).  Thus, UCP1 activation by fatty acids 
is an essential component of adaptive non-shivering thermogenesis.  
Based on our understanding of the thermogenic capabilities of UCP1 on 
metabolic inefficiency and obesity, one would expect that the absence of UCP1 would 
result in reduced capacity to burn fat and energy.  However, it was surprising and 
somewhat counterintuitive that UCP1 knockout mice were protected from diet-induced 
obesity in a manner that was highly dependent on environmental temperature (Enerback 
et al. 1997).  These mice were only susceptible to diet-induced obesity when housed at 
thermoneutrality, the state at which the body does not need to make additional heat to 
maintain core body temperature, and thus does not require UCP1 activity (X. Liu et al. 
2003).  These findings further bolster the association between adaptive non-shivering 
thermogenesis and weight regulation, and more importantly, suggest that in the absence 
of UCP1, alternative pathways of non-shivering thermogenesis exist to maintain core 
body temperature. 
1.5.2 Characterization of UCP3 
 The UCP1 homolog, UCP3, shares more than 50% amino acid homology with 
UCP1 and has been shown to regulate proton flux (Jaburek et al. 1999; Boss et al. 2000). 
Compared to UCP1, UCP3 is more broadly expressed and can be found in various tissues 
including heart, SKM, BAT (Vidal-Puig et al. 1997), and as we recently demonstrated, 
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skin (Lago et al. 2012).  Given its diverse tissue expression in highly metabolic tissues, it 
has been postulated that UCP3 may play a more extensive role in whole body energy 
balance.  
 In the UCP field, a great deal of controversy exists regarding UCP3 as a 
physiological thermogenic regulator.  Soon after its identification in 1997, UCP3 
knockout mice were generated and shown to have no thermogenic phenotype when 
exposed to cold (Gong et al. 1997).  However, the mere lack of a cold-phenotype in the 
UCP3 knockout mice could be due to the existence of compensatory processes that 
enable these mice to fulfill their heat requirements in response to cold, and thus does not 
necessarily rule out the involvement of UCP3 in alternative mechanisms of non-shivering 
thermogenesis.  
There are several lines of evidence to support the thermogenic capacity of UCP3 
in response to certain pharmacological agents and hormonal stimuli, particularly in SKM. 
Thyroid hormone, a key endocrine regulator of thermogenesis and energy balance (Silva 
1995), is closely tied to UCP3 activation by numerous studies demonstrating that changes 
in thyroid status can alter UCP3 gene expression  (Gong et al. 1999;Larkin et al. 1997).  
Consistent with these findings, studies utilizing a β1/β2/β3-adrenoreceptor knockout (β-
less) mouse model that possesses a severely cold-intolerant phenotype, showed that 
administration of 3,5,3’ triiodothyronine (T3), an active form of thyroid hormone, 
significantly increased UCP3 expression in SKM and also rescued cold-induced 
thermogenesis in these mice (Flandin et al. 2009).   
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UCP3 has also been shown to be a key molecular mediator in toxicant-induced 
hyperthermia.  Amphetamine type drugs, also known as sympathomimetics such as 
methamphetamine and 3,4-methlenedioxymethamphetamine (MDMA, Ecstasy), can 
trigger life-threatening hyperthermia.  Interestingly, mice lacking UCP3 exhibit severely 
blunted hyperthermic responses to MDMA and are protected from the lethal effects of the 
drug (Mills et al. 2003).  Moreover, in terms of the underlying mechanism of UCP3 
activation in sympathomimetic induced hyperthermia, it has been shown that Meth 
administration leads to the phosphorylation of UCP3 and subsequent increase in proton 
leak (Kellya et al. 2012).  
1.5.2.1 Physiological relevance of UCP3  
 Despite the controversy surrounding the thermogenic capacity of UCP3, it 
remains an attractive target in the treatment of obesity and related metabolic diseases.  
Another prominent area of UCP3 research is devoted to its role in modulating 
mitochondrial ROS production.  Researchers believe that the excess generation of ROS 
from the chronic pressure exerted on the ETC due to overnutrition could explain how an 
obese state can lead to the development of insulin resistance.  This proposed mechanism 
centers on the premise that chronic oversupply of mitochondrial oxidative substrates such 
as lipids, sugars, and amino acids likely facilitate a metabolic environment that is 
favorable to the generation of ROS (Morino et al. 2006; Muoio & Newgard 2008). 
Interestingly, mice under-expressing UCP3 showed evidence of significantly higher 
levels of oxidative damage (Brand et al. 2002).  Furthermore, numerous studies have 
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shown that UCP3 in SKM can lower mitochondrial ROS generation (MacLellan, Gerrits, 
Gowing, P. J. S. Smith, Wheeler & Harper 2005a) and protect against oxidative stress in 
SKM (Barreiro et al. 2009).  These studies, taken together with the fact that superoxide 
activates UCP3 (Echtay et al. 2002) has led to a proposed feedback mechanism in which 
elevated levels of ROS production activate UCP3 to mitigate the generation of these free 
radicals and protect against oxidative stress.   
 In addition to its potential role in the protection against oxidative stress and non-
shivering thermogenesis, it has also been proposed that UCP3 plays an important role in 
facilitating complete fatty acid oxidation and transport (Himms-Hagen & Harper 2001; 
Brand & Esteves 2005).  Mice that overexpress UCP3 in SKM have higher levels of fatty 
acid oxidation (Bézaire et al. 2005; MacLellan, Gerrits, Gowing, P. J. S. Smith, Wheeler 
& Harper 2005a) and show reduced circulating levels of biomarkers for incomplete β-
oxidation (Aguer et al. 2013). The evidence supporting the involvement of UCP3 in 
facilitating efficient and complete fatty acid oxidation suggests a protective role for this 
protein in obesity-induced insulin resistance.  Indeed, studies in UCP3 heterozygous mice 
with reduced levels of UCP3 protein expression in SKM exhibited impaired rates of fatty 
acid oxidation, along with a clear deterioration in insulin signaling when fed high fat 
diets (Senese et al. 2010).  Taken together, these studies emphasize the importance of 
characterizing the underlying mechanisms that link fatty acid metabolism to UCP3 given 
the current obesity epidemic in the US.   
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1.6 Dissertation objectives 
 In the search to develop new therapeutics to treat obesity, the generation of 
various novel transgenic animal models has allowed researchers to identify specific 
molecular targets that can alter body weight and promote insulin sensitivity.  A common 
underlying mechanism in many of these obesity-resistant animal models is elevated 
energy expenditure (Reitman 2002).  Aside from physical activity, an increase in energy 
expenditure/demand can only occur through thermogenic processes (i.e. uncoupling and 
futile cycling) that promote energy inefficiency. 
The most well described mechanism of thermogenesis is inducible mitochondrial 
proton leak via uncoupling proteins. UCPs belong to a conserved class of mitochondrial 
anion / solute carrier superfamily of proteins that are expressed in the inner mitochondrial 
membrane and have the unique ability to uncouple substrate oxidation from ATP 
generation by allowing protons to leak back into the matrix and circumvent ATP 
synthase.  By promoting metabolic inefficiency and increasing energy expenditure, 
mitochondrial uncoupling can drive substrate oxidation to relieve the persistent pressure 
on the ETC from nutrient overload, and also lower mitochondrial ROS production.  
UCP1, the canonical uncoupling protein expressed almost exclusively in BAT, is 
recognized as the master regulator of adaptive non-shivering thermogenesis.  Indeed, 
UCP1 knockout mice are extremely sensitive to cold temperatures (Golozoubova et al. 
2001), and are also susceptible to diet-induced obesity when housed at thermoneutrality 
(Feldmann et al. 2009). However, when it comes to the other UCP homologues, including 
UCP3, the molecular mechanisms underlying its thermogenic actions are unclear.  Even 
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though UCP3 knockout mice exhibit normal thermoregulatory responses to cold and do 
not possess a clear metabolic phenotype (Vidal-Puig et al. 2000), UCP3 overexpression 
in SKM is positively associated with improved glucose homeostasis(Choi et al. 2007; 
Huppertz et al. 2001), increased fatty acid oxidation (MacLellan, Gerrits, Gowing, P. J. S. 
Smith, Wheeler & Harper 2005a; Aguer et al. 2013; Bézaire et al. 2005), and enhanced 
energy expenditure in SKM(Clapham et al. 2000).   
Given that mitochondrial uncoupling can counteract the metabolic derangements 
seen with obesity-induced insulin resistance, we set out to characterize the mechanisms 
by which UCP3 controls thermogenesis, fatty acid oxidation, and SKM metabolism.  We 
hypothesized that SKM is the primary site of UCP3-dependent thermogenesis, and that it 
is interacting with key metabolic proteins involved in maintaining energy balance during 
nutrient overload.  To test this hypothesis, we focused on the following aims: (1) defining 
the role of SKM UCP3 in regulating sympathomimetic-induced thermogenesis (2) 
identifying key UCP3-protein interactions in SKM (3) characterizing the interaction 
between UCP3 and the auxiliary unsaturated fatty acid metabolizing enzyme, ECH1.  
Collectively, this investigation highlights the importance of UCP3 in regulating 
thermogenesis and energy balance in SKM.  Furthermore, the work shown here 
establishes a novel mechanism by which complex formation between UCP3 and ECH1 
coordinates an increase in fatty acid metabolism and energy demand to protect against 





Chapter 2: Materials and Methods 
 
2.1 Chemicals and reagents 
 Unless otherwise noted, all reagents were purchased from Sigma (St. Louis, MO). 
2.2 Plasmid DNA constructs 
 Full-length UCP3, UCP1 and ECH1 genes were amplified from mouse heart 
cDNA library and cloned into pcDNA3.1 (Invitrogen, Carlsbad, CA) with either the C-
terminal V5 or Myc tag, respectively.  
 
2.2.1 Quickchange site-directed mutagenesis 
 Site-directed mutagenesis of plasmids to generate the C-terminal Myc tagged 
ECH1 catalytic mutants and the C-terminal V5 tagged UCP3 truncation mutants was 
carried out with Platinum pFX DNA polymerase from (Life Technologies, Grand Island, 
NY), following the manufacturer’s protocols for site-directed mutagenesis.  The primers 
used to generate the Myc tagged- ECH1 catalytic mutants were previously published in 
Zhang et al.   
 
2.3 Cell culture 
 HEK293T and C2C12 cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA).  HEK293T cells were cultured at 37°C with 5% CO2 
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in Dulbecco’s Modified Eagle Medium (Cellgro, Manassas, VA) containing 10% Fetal 
Bovine Serum1% and 100X PenG- Streptomycin (Invitrogen, Carlsbad, CA).  C2C12s 
were cultured in similar conditions, with the exception of being grown in high glucose 
(45000mg/L), Dulbecco’s Modified Eagle Medium from Sigma (St. Louis, MO). 
2.3.1 Transient transfection of cells 
 HEK293Ts were plated one day prior to transfection and were transfected with 
either calcium phosphate or TransIT-LT1 (Mirus, Madison, WI) following the 
manufacturer’s instructions.  To improve transfection efficiency of C2C12s, a cell line 
that is generally difficult to transfect, cells were transfected with Lipofectamine 2000 at a 
2:1 ratio (Invitrogen, Carlsbad, CA) immediately after plating cells, according to Mercer 
et al. 
2.3.2 Generation of stable C2C12 cell lines  
 The Precision LentiORF lentiviral packaging system was obtained from Thermo 
Fisher Scientific (Waltham, MA). Full-length ECH1 was cloned into the pLOC lentiviral 
plasmid following the manufacturer’s instructions.   
 HEK293T packaging cells were transfected with the pLOC lentiviral plasmid and 
two viral packaging plasmids pMDG2 and psPAX2, using a standard calcium phosphate 
transfection method to produce the lentiviral particles. The HEK293T cells were 
incubated with the transfection complexes in normal growth media supplemented with 
25µM choloroquinone for 8 hours.  Forty hours after transfection, the virus containing 
media was harvested.  To concentrate the lentiviral particles, the Lenti-X Concentrator 
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reagent (Clonetech, Mountainview, CA) was used according to the manufacturer’s 
protocols.  
 For lentiviral transduction, C2C12 myocytes were seeded in 6 well plates at 
50,000 cells/wells one day prior to infection.  The cells were then incubated with the 
concentrated lentiviral particles in full growth media supplemented with polybrene 
(8µg/mL), overnight.  Following infection, stable cell colonies were selected with 
25µg/mL of blasticidin.  Positive colonies were then confirmed through immunoblotting 
and densitometry.   
2.4 Animals 
 C57BL/6J wild-type mice were obtained from Jackson Laboratories (Bar Harbor, 
ME).  The UCP3 knockout mice (UCP3-/-) in the C57BL/6J background were a gift from 
Dr. Marc Reitman, formerly of the National Institutes of Health. The UCP1 knockout 
mice (UCP1-/-) were a gift from Dr. Leslie Kozak of the Pennington Biomedical Research 
Institute.   The UCP3 -/- mice were crossed with the UCP1-/- mice to generate our UCP1 
and UCP3 double knockout line (UCP1-/- + UCP3-/-).  The transgenic mice 
overexpressing human UCP3 in SKM generated from human alpha1-actin promoter 
targeting construct (TgSKM UCP3 +/+) were a gift from Dr. Mary-Ellen Harper of the 
University of Ottawa. The TgSKM UCP3 +/+ were then crossed with the UCP3 -/- and 
DKO lines to generate a transgenic mouse overexpressing human UCP3 in SKM in the 
UCP3-/- and DKO background (TgSKM UCP3 -/- and TgSKM UCP1-/- + UCP3-/-, 
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respectively).  It is important to note that all TgSKM-UCP3 strains were kept as 
hemizygous breeder colonies.  
 Unless otherwise noted, all experiments were performed in male mice between 
the ages of 6-8.5 weeks.  All animal husbandry and procedures were carried out in 
accordance to the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) and approved by the Institutional Animal Care and Use Committee at 
The University of Texas at Austin (IACUC).   
2.4.1 Generation of ECH1 -/- mouse model 
 The custom designed CompoZr® Zinc Finger Nuclease Plasmid targeted to exon 3 
of the mouse ECH1 gene on chromosome 7 was obtained from Sigma.  In-vitro 
transcription of the ZFN mRNA was performed following the manufacturer’s 
instructions.  mRNA was transfected in cultured cells to validate activity using  a Cel-I 
enzymatic mutation detection assay.   The ZFN mRNA (10ng/µl) was then microinjected 
into 330 mouse BDF1 embryos and implanted into pseudopregnant female mice 
recipients.    
 Genotyping of founders (F0) was done using genomic PCR with the primers 
following primers provided by Sigma, forward 5’-CGCGATGACAGTTTCCAGTA-3’ 
reverse 5’-CAAACAAAAACCCACTGAGGA-3’. In order to perform DNA sequence 
analysis, amplified bands of the ZFN target site were cloned in to the pGEM-T Easy 
Vector system (Promega, Madison, WI) and sequenced by the University of Texas at 
Austin’s DNA Sequencing Facility.  Two founders (line 3 and 11) were then selected for 
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backcrossing and then mated with the wild-type C57BL/6J mice.  Speed congenics was 
performed to select the heterozygous males from each generation for breeding, and to 
ensure that >99% of the BDF1 background was replaced with the C57BL/6J background.  
Line 11 was backcrossed a total of 6 generations before proceeding with experiments.  
2.4.2 Diet induced obesity studies 
 At the age of three weeks, mice (n=8) were placed on high fat chow (60% fat 
kCal, TD.06414) or control chow (10% fat kCal, TD.0.8806)) for 6 weeks.  All diets 
were provided from Teklad Laboratories (Chicago, IL).  At the end of the 6 week 
treatment period mice were sac’d and mitochondria was extracted from SKM and BAT 
using the previously described procedure. 
 2.4.3 Intraperitoneal temperature probe placement 
 Male mice between 6-7 weeks of age, weighing between 20-25 grams were used 
for all experiments. All surgical tools and operating areas were prepared under sterile 
technique procedures.  The right dorsal flank of each mouse was shaved and cleaned with 
sterile povidine solution. The mice were then anaesthetized with isoflurane via nose cone 
and administered a preoperative subcutanous injection of 5mg/kg carprofen.  A transverse 
oblique incision was made dorsally above the iliac crest, followed by another incision 
through the peritoneal wall.  The wireless temperature probe by Starr Life Sciences Corp 
(Oakmont, PA) was then inserted into the peritoneal cavity.  The incision on the 
peritoneal wall was closed with nonabsorbable Vicryl sutures.  Lastly, the skin was 
closed using sterile skin clips.   The following day, mice were given a postoperative 
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subcutaneous injection of carprofen.  The mice were closely monitored for any signs of 
distress or infection after surgeries. 
2.4.4 Thermogenic drug administration  
  Following the intraperitoneal temperature probe placement surgery, mice were 
given a one week recovery period prior to experiments. All injections were performed in 
a temperature-controlled chamber at 25°C.  Mice were weighed and placed in 
individually housed cages with 50g of fresh bedding.   Baseline temperatures were 
recorded and mice were then administered a subcutaneous injection, at the nape of the 
neck, of either methamphetamine (20mg/kg) or norepinephrine (1mg/kg) dissolved in 
sterile saline.  Core body temperatures were monitored and recorded every minute using 
the VitalView Software (Starr Life Sciences, Oakmont, PA). 
 
2.4.5 Fasting and cold-exposure studies  
 Male mice between the ages of 7.5-8.5 weeks old were fasted for 18hrs in 
individually housed cages with fresh bedding. The body weight of each mouse was 
recorded before and after fasting treatment.  Any mouse under 21g was excluded from 
the study. 
 Cold tolerance was then tested by placing mice in a temperature-controlled room 
at 4°C for 3-6 hours, or until body temperature dropped below 25°C.  Core body 
temperatures was recorded prior to cold-exposure and every hour during treatment with a 
rectal temperature probe (Physitemp, Clifton, NJ) .  
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2.5 Isolation of mitochondria from cell and animal tissues 
 C2C12 cells were homogenized with a 27.5 gauge needle in CP-1 buffer 
supplemented with protease and phosphatase inhibitors.  Homogenates were then 
centrifuged at 500g for 10 minutes at 4˚C twice, making sure to discard pellets and re-
aliquot supernatant in to new tubes in between spins.   After second spin, the supernatant 
was collected and spun at 10,500 g for 10 minutes at 4˚C to pellet mitochondria.  
 Brown adipose tissue, SKM, and heart tissue samples were isolated from mice 
and finely minced in either CP-1 buffer or 100mM KCl, 500mM Tris-HCl, 2mM EGTA, 
1mM ATP, 5mM MgCl2, 0.5% BSA, pH 7.4 supplemented with protease and phosphatase 
inhibitors.  Tissues were then homogenized with a Teflon pestle drill press in smooth glass 
homogenizers.  Homogenates were then centrifuged at 800g for 10 minutes at 4˚C twice, 
making sure to discard pellets and re-aliquot supernatant in to new tubes in between 
spins. After the second spin, homogenates were applied to a 70µm cell strainer and then 
centrifuged at 10,500g for 10 minutes at 4˚C to pellet mitochondria.  
2.6 Immunoprecipitation and mass spectrometric analysis 
 Mitochondria were isolated from SKM of wild-type C57BL/6J mice and UCP3 -/- 
following the previously described method of mitochondrial isolation from animal 
tissues.  Mitochondrial pellets were resuspended in immunoprecipitation buffer (50mM 
Tris-HCL 300mM NaCl, 1% Triton X-100 supplemented with 200 µM PMSF, 1µg/ml 
Leupeptin, 1µg/ml Pepstatin A, 100 U/ml Aprotonin, 200 µM Sodium Orthovanadate, 
and 100 mM Sodium Fluoride) and lysed with a bead mill homogenizer for 10 minutes at 
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4˚C.  Mitochondrial protein was quantified using a bicinchoninic acid assay (Pierce 
Biotechnology, Rockford, IL).   
Immunoprecipitation samples were prepped in 600µl immunoprecipitation buffer 
and incubated with rabbit polyclonal α-UCP3 (custom antibody generated by Washington 
Biotechnology, Columbia, MD) at 1:50 dilution for ~16 hours at 4˚C with rotation. Prior 
to adding Protein G Sepharose beads (Pierce Biotechnology, Rockford, IL) to samples, 
the beads were blocked in 5% BSA in PBS at 4˚C for 16 hours with rotation. Protein G 
Sepharose beads (1:50 dilution) were added to each immunoprecipitation sample and 
rotated at 4˚C for 5 hours.  Beads were washed 8 times before protein elution.  Samples 
were then prepared for SDS polyacrylamide gel electrophoresis (PAGE) using a BioRad 
precast gel (BioRad, Hercules, CA).   
 The coomassie stained protein complex band was cut out of gel and submitted to 
the ICMB Proteomics Facility at the University of Texas at Austin. Results were 
analyzed via the Scaffold 3 software (Proteome Software, Portland, OR). 
 2.7 Immunoblotting 
Lysates were prepared in RIPA buffer (50mM Tris-HCl, 1% NP40, 0.5% Sodium 
Deoxycholate, 0.1% Sodium Dodecyl Sulfate (SDS), 150mM Sodium Chloride (NaCl), 
2mM EDTA, pH 8.0) supplemented with protease and phosphatase inhibitor cocktails 
(Roche, Nutley, NJ). A bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL) 
was used to quantitate proteins.  
Nitrocellulose membranes were probed with the following primary antibodies; 
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rabbit polyclonal α-V5 (Abcam, Cambridge, MA), mouse monoclonal α-V5 (Life 
Technologies, Grand Island, NY), α-mouse monoclonal α-myc (Cell Signaling, Danvers, 
MA), rabbit polyclonal α-ECH1 (custom antibody generated by Washington 
Biotechnology, Columbia, MD), rabbit polyclonal α-ECH1/ECH1 (Abcam, Cambridge, 
MA), rabbit polyclonal α-UCP3 (custom antibody generated by Washington 
Biotechnology, Columbia, MD), and rabbit polyclonal anti-UCP3 (Abcam, Cambridge, 
MA).  Following incubation with primary antibodies, the nitrocellulose membranes were 
probed with α-rabbit-HRP or α-mouse-HRP (GE Healthcare, Piscataway, NJ).  
Membranes were developed using Super Signal West Pico chemiluminescent (Pierce 
Biotechnology, Rockford, IL). 
2.8 Co-immunoprecipitation 
Immunoprecipitation samples (IP) were prepared using 250-500µg of protein and 
adjusted to 300µl with the previously described immunoprecipitation buffer.  Samples 
were then incubated with either 1µg of primary antibody or IgG (for controls) at 4˚C for 
16 hours with rotation. Protein G Sepharose beads were blocked in 5% BSA in PBS 
overnight as previously described.  Thirty microliters of Protein G Sepharose beads were 
then added to each immunoprecipitation sample and rotated at 4˚C for 5 hours.  Samples 
were washed 8 times with wash buffer, after then prepared for SDS polyacrylamide gel 




2.9 Quantitative RT-PCR 
Total RNA was extracted from C2C12 cells and mouse tissues using the TRIzol® 
reagent (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions.  RNA was 
then reverse transcribed using the TaqMan® Reverse Transciption Kit (Life 
Technologies, Grand Island, NY) and quantative RT-PCR was performed with the SYBR 
Green dye using a real-time PCR system (Bio-Rad, Hercules, CA).  The following 
primers used for amplification are listed in appendices. Experiments were repeated in 
triplicates and data represent fold change relative to levels of GAPDH. 
2.10 Immunocytochemistry 
Twenty-four hours after transfection C2C12s were fixed and permeabilized in 
2.5% paraformaldehyde and 0.1 % TritonX-100 at RT for 20 minutes.  The cells were 
then incubated with either anti-Myc or the peroxisomal marker anti-catalase (Abcam, 
Cambridge, MA), followed by secondary anti-mouse Alexa 568 or anti-rabbit Alexa 488.  
All fluorescent images were acquired with a Nikon Eclipse Ti-S microscope, 60x Nikon 
Plan Apo VC Oil objective with numerical aperture 1.40.  Images were captured with 
Photometrics Coolsnap EZ camera and processed using Nikon NIS Elements BR 3.0 
software. 
2.11 Myocyte oxygen consumption 
Respiration rates in SKM myocytes were quantified using a fiber-optic 
fluorescence oxygen monitoring system (Instech Laboratories, Plymouth Meeting, PA). 
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Three million cells were added to the 1mL chamber containing Dulbecco’s Modified 
Eagle Medium from Sigma (St. Louis, MO).  Basal and oligomycin-induced uncoupled 
respiration rates were determined from linear regions of the slope observed after each 
treatment. 
2.12 Fatty acid oxidation 
C2C12 stable cell lines were grown in a 24-well plate were transiently transfected 
and assayed for oleate oxidation using the method of Mao et al. (39).  Briefly, myocytes 
were serum starved for 2 hours in substrate-limited media.  They were then incubated in 
1µC/ml 14C-oleic acid (American Radiolabeled Chemicals, St. Louis, MO), lysed with 
70% percholoric acid, and collected radioactivity was measured using a scintillation 
counter. 
2.13 Statistics 
 Analysis of variance comparisons between genotypes were analyzed by a 
student’s t-test or single factor ANOVA followed by Tukey’s post hoc test, with a p<0.05 




Chapter 3: SKM UCP3 in sympathomimetic-induced hyperthermia 
 
3.1 Introduction  
As discussed earlier, there are various pharmacological and toxicological agents 
that can alter the normal mechanisms of thermoregulation and trigger different metabolic 
pathways of heat-generation, thus resulting in life-threatening hyperthermia. Although 
the thermogenic capacity of UCP3 in SKM has been greatly debated since its discovery, 
there have been several lines of evidence to support its role as a thermogenic effector in 
response to certain pharmacological agents known as sympathomimetics, which include 
methamphetamine (Meth) and 3,4-methylenedioxymethamphetamine (MDMA) 
(Sprague, Mallett, et al. 2004).  Foremost, the strongest evidence shows that UCP3 
knockout mice have severely blunted (80-100%) thermogenic responses to MDMA in 
vivo (Mills et al. 2003). 
Despite the mounting evidence implicating UCP3 function in sympathomimetic-
induced hyperthermia, the mechanisms that regulate SKM UCP3-dependent 
thermogenesis in this model remain unclear.  SNS activation of BAT UCP1 through fatty 
acids is the most well characterized mechanism of non-shivering thermogenesis.  Given 
the close association between fatty acids and UCP3 activity it is possible that UCP3 
activity in SKM is regulated in a similar fashion through NE stimulation of fatty acids 
released from white adipose tissue.  However, Meth administration can also have 
complex effects on thermogenesis that are independent of the SNS.  Indeed, there is also 
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a significant amount of evidence to demonstrate that thyroid hormone (TH) also plays a 
pivotal role in Meth-induced hyperthermia and UCP3 regulation in SKM (Sprague et al. 
2007; Sprague, Mallett, et al. 2004; Nicholls & Locke 1984b).  
There are several components of sympathomimetic-induced hyperthermia, and in 
addition to SKM, it has also been proposed that BAT also plays an important role in this 
response.  Although UCP3 protein expression can be found in SKM and BAT, its activity 
is not well studied.  Indeed, UCP1 in BAT is recognized as the primary regulator of non-
shivering thermogenesis in this tissue in response to cold (Nedergaard et al. 2000). The 
original postulation that adult humans did not possess significant amounts of BAT led 
researchers to believe that BAT did not contribute to adult thermogenic processes, 
including sympathomimetic-induced hyperthermia.  However, advancements in medical 
imaging technology have revealed that BAT is not only present in adult humans 
(Nedergaard et al. 2007; Bar-Shalom et al. 2004), but also that certain depots of white 
adipose tissue can be converted to BAT with the treatment of certain sympathetic 
mimetics (Townsend & Tseng 2014).  Furthermore, recent surgical BAT ablation 
experiments performed by Sanchez- Alavez et al. revealed that BAT contributes to 40% 
of Meth-induced hyperthermia (Sanchez-Alavez et al. 2013).  In light of these new 
findings, characterizing the contribution of SKM UCP3 and BAT UCP1 in adult 
thermogenic processes will reveal key information about the interplay between different 
thermogenic pathways.  
Herein, we utilize a transgenic UCP3-/- mouse model that specifically expresses 
human UCP3 at physiological levels in SKM (TgSKM UCP3-/-) to demonstrate that SKM 
 
 52 
UCP3 is key in regulating sympathomimetic-induced thermogenesis.  We then focused 
on defining the role of SNS activation on UCP3-dependent thermogenesis in SKM.   
Lastly, we investigated the relationship of UCP1 and UCP3-dependent thermogenesis in 
response Meth-induced hyperthermia, and show that the presence of UCP1 and UCP3 are 
both key components in the development of hyperthermia in response to Meth.  
3.2 Results 
3.2.1 UCP3 expression in SKM is a key effector in sympathomimetic-induced 
thermogenesis 
Given that SKM is thought to play a significant role in sympathomimetic-induced 
thermogenesis, we focused on investigating the thermogenic capacity of UCP3 in SKM.   
Although UCP3 can be found in SKM and BAT, its expression in BAT is relatively 
small, especially when compared to the concentrations of BAT UCP1, which accounts for 
10% of total membrane protein (Brand & Esteves 2005).  Therefore, the blunted Meth-
induced thermogenic response previously seen in UCP3-/- mice (Sprague, Brutcher, et al. 
2004) is likely due to the lack of UCP3 expression in SKM rather than BAT.  Therefore, 
we directed our efforts to characterizing UCP3 activity in SKM by crossing the UCP3-/- 
line with the TgSKM UCP3-/- mice.  The resulting TgSKM UCP3-/- strain was a UCP3 
null mouse that overexpressed UCP3 specifically in SKM alone (Figure 3.1 A).  
Consistent with previous findings, the UCP3-/- mice demonstrated a blunted thermogenic 





Figure 3.1 UCP3-dependent thermogenesis in Meth-induced hyperthermia 
(A)  UCP3 expression in mitochondrial lysates isolated from SKM (SKM) and brown 
adipose tissue (BAT).  Mitofusion 2 (Mfn2) and DNA polymerase ϒ (DNA pol ϒ) were 
used as loading controls.  (B) Changes in core body temperature from baseline after 
subcutaneous injection of Meth (20mg/kg).  (C) Peak change in core body temperature 
from baseline after Meth injection (20 minutes).  














able to restore Meth-induced thermogenesis in the TgSKM-UCP3 -/- mice similar to the 
wild-type group (C57BL/6J) (Figure 3.1 B-C). 
Another important issue regarding the mechanisms of sympathomimetic-induced 
hyperthermia is whether UCP3 activation is directly or indirectly mediated by SNS via 
NE. Sympathomimetic drugs have the ability to increase thermogenesis through 
adrenergic stimulation.  Data showing that levels of circulating NE spikes (35-fold) in the 
bloodstream 30 minutes prior to peak MDMA-induced hyperthermia (Sprague et al. 
2005) suggests that adrenergic signaling through NE is key in mediating this thermogenic 
response.  Furthermore, it has also been shown that combined antagonism of the α1- and 
β3 adrenergic receptors reverses and inhibits MDMA-induced hyperthermia(Sprague, 
Brutcher, et al. 2004).  However, it is important to note that these drugs can also affect 
thermogenesis through their indirect actions on the hypothalamic-pituitary-adrenal and 
hypothalamic-pituitary-thyroid axes (Sprague, Brutcher, et al. 2004; Sprague et al. 2003).  
Additionally, the generation of ROS has also been implicated as a contributing regulator 
of Meth-induced hyperthermia, in a pathway independent of SNS activation (Sanchez-
Alavez et al. 2013).  Given that UCP3 activity has been linked to thyroid hormone 
(Solanes et al. 2005) and ROS (Echtay et al. 2003), it is possible that UCP3-dependent 
thermogenesis in response to Meth is not directly mediated through SNS activation. To 
test this, we administered NE (1mg/kg, s.c.) to UCP3-/- mice and found that even though 
peak-thermogenesis was slightly depressed in the UCP3-/- mice compared to the wild-
type group, the difference was not statistically significant (Figure 3.2 A-B).   These 
results demonstrate that NE is not a direct regulator of UCP3-dependent thermogenesis. 
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3.2.2 Interplay between UCP1 and UCP3 in sympathomimetic-induced 
thermogenesis 
As previously discussed, BAT and SKM tissues have both been shown to 
contribute to Meth-induced hyperthermia.  In order to characterize the effect of 
uncoupling-dependent thermogenesis in these distinct tissues we generated a global, 
double knockout strain lacking UCP3 and UCP1 (UCP1-/- + UCP3 -/-). We then focused 
on further scrutinizing the thermogenic capacity of UCP3 in SKM by generating a novel 
double UCP1 and UCP3 global knockout mouse line, that specifically overexpressed 
human UCP3 in SKM (TgSKM UCP1-/- + UCP3-/-) (Figure 3.3 A).  In characterizing 
these mice, we found that body weight was significantly reduced in the TgSKM UCP3-/- 
and TgSKM UCP1-/- + UCP3-/- compared to the wild-type, single UCP-knockout, and 
double UCP-knockout mice (Figure 3.2 B).  This was not too surprising given that it has 
been previously shown that mice expressing human UCP3 transgene off the α-skeletal 
actin promoter are leaner, and have a marked reduction in adiposity (Clapham et al. 
2000). Furthermore, there were no significant differences in body weight among wild-
type, UCP1-/-, UCP3-/-, and UCP1-/- + UCP3 -/- (Vidal-Puig et al. 2000; Gong et al. 2000).   
Although, BAT has been previously shown to play an important role in Meth-
induced hyperthermia, the direct contribution of UCP1 has not been defined.  In order to 





Figure 3.2 The sympathetic nervous system is not a direct regulator of UCP3-
dependent thermogenesis  
 (A) Changes in core body temperature from baseline after subcutaneous injection of 
norepinephrine (NE, 2mg/kg).  (D) Peak change in core body temperature from baseline 
after norepinephrine (20 minutes).  






Figure 3.3 SKM UCP1 and UCP3 both contribute to Meth-induced thermogenesis 
 (A) UCP1 and UCP3 expression in mitochondrial lysates isolated from BAT and SKM 
tissues. (B) Body weights of mice between 7-8 weeks of age fed normal chow diet    
(n=9-42). (C) Changes in core body temperature from baseline after subcutaneous 
injection of Meth (20mg/kg).  (D) The area under the curve (TAUC) for 60 minutes post 
injection (n=5-7).  
Data are expressed as mean +/- SEM. ##p<0.01, ###p<0.001, differences compared to 









































to UCP1-/- mice and found that they exhibited a delayed and blunted thermogenic 
response similar to the UCP3-/- (Figure 3.3 C).  Indeed, 20 minutes post injection, the 
core body temperature of the UCP1-/- mice dropped below baseline.  This data, taken with 
our previous findings that UCP3 in SKM is important in Meth-induced thermogenesis, 
argues that SKM UCP3 and BAT UCP1 both contribute to the hyperthermic response 
seen with Meth administration.  We then focused on answering the question of whether 
regulation of UCP-dependent thermogenesis in these two distinct tissues was interrelated 
in response to Meth using our single, double UCP knockout, and transgenic SKM UCP3 
mouse lines.  As expected, the UCP1-/- + UCP3-/- double knockout mice displayed an 
even more exaggerated thermogenic phenotype post Meth injection than the single 
knockout strain.  Interestingly, the TgSKM UCP1-/- + UCP3-/- mice also did not exhibit a 
hyperthermic response, despite the presence of UCP3 in SKM.  Taken together, these 
results suggest that UCP1-dependent BAT thermogenesis plays a key role in regulating 
the contribution of UCP3-dependent thermogenesis in SKM.  
Analysis of the area under the curve (AUC, Figure 3.3 D) of core body 
temperature in in the first 60 minutes post Meth injection was used to quantify the initial 
changes caused by Meth and the influence of BAT UCP1 and SKM UCP3. The AUC 
data revealed that UCP3 in SKM contributes to ~50% of METH-induced thermogenesis 
within the first 60 minutes, whereas UCP1 accounts for ~75% of the initial response. 
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 3.3 Discussion 
 As discussed earlier, there are several lines of evidence to suggest that UCP3 
regulates SKM thermogenesis in Meth-induced hyperthermia.  Our observations strongly 
support the thermogenic capabilities of UCP3 in SKM by using a mouse model that 
specifically expresses human SKM UCP3 in a global UCP3 knockout background.  In 
contrast, to the well-described pathways of SNS regulation of BAT UCP1-dependent 
thermogenesis in response to cold temperatures, the mechanisms that regulate UCP3-
dependent thermogenesis in SKM are less characterized.  Here we show that unlike BAT 
UCP1, NE is not a direct regulator of UCP3-dependent thermogenesis in 
sympathomimetic-induced hyperthermia. Therefore, it is likely that there are pathways 
independent of SNS activation that could be contributing to UCP3-dependent 
thermogenesis in SKM.  These indirect pathways of Meth-induced hyperthermia could 
possibly be mediated through thyroid hormone or ROS generation, which are both 
physiological mediators that are also associated with UCP3 activation.  Our data imply 
that strategies that target UCP3 function independent of SNS activation may be an 
effective therapeutic approach to treating toxicities seen with sympathomimetics.    
 We also demonstrate that UCP-dependent thermogenesis in BAT and SKM both 
contribute to Meth-induced hyperthermia.  Furthermore, our findings imply that Meth-
induced hyperthermia may be a result of an integrated response between uncoupling in 
BAT and SKM, where BAT UCP1 part of the initial response to Meth and also mediates 
UCP3 activation in SKM.  These findings are consistent with additional studies that 
suggest crosstalk between SKM and BAT exists and is important in regulating whole 
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body thermogenesis (Lee et al. 2014).  Taken together, the data suggests that UCP1-
mediated crosstalk between SKM and BAT may represent a novel thermogenic axis that 





Illustration 3.1 Proposed model of UCP-dependent thermogenesis in response to 
amphetamines  
There are several mechanisms that contribute to amphetamine-induced thermogenesis.  In 
response to amphetamine-like agents (MDMA and Meth), hypothalamic neurons activate 
the sympathetic nervous system and leads to peripheral release of norepinephrine (NE). 
NE binds to the β3- adrenergic receptors on target tissues including, white adipose tissue 
(WAT) and brown adipose tissue (BAT), to initiate a signaling cascade that leads to 
lipolysis of triglyceride stores and subsequent release of free fatty acids (FFA). The FFAs 
serve as substrates for mitochondrial β-oxidation and directly activate uncoupling in BAT 
and SKM tissues.  In this model, UCP3 in SKM is part of an integrated response with 
UCP1 in BAT that contributes to hyperthermia.  It is also possible that these 
amphetamine-like agents can have indirect thermoregulatory effects through UCP3 




Chapter 4: Identification of UCP3-protein interaction networks 
 
4.1 Introduction 
The ability of mitochondria to appropriately switch freely between different 
energetic substrates (lipids, glucose, amino acids) in various nutritional and physiological 
circumstances is thought to be a key factor in maintaining energy homeostasis and 
protecting against obesity-induced metabolic dysregulation.  Thus, understanding the 
mechanisms that guide nutrient partitioning and metabolic flexibility in mitochondria is 
an attractive approach to treat obesity and its late stage complications.  
There are numerous studies to support the importance of UCP3 in maintaining 
energy balance in various physiological contexts.  Studies have shown that 
overexpression of UCP3 in SKM not only increases fatty acid metabolism and protects 
against oxidative stress (MacLellan, Gerrits, Gowing, P. J. S. Smith, Wheeler & Harper 
2005b) but also improves glucose homeostasis (Choi et al. 2007; Huppertz et al. 2001).  
Indeed, there are numerous clinical studies that associate altered UCP3 expression and 
function to the pathophysiology of obesity, insulin resistance, and the development of 
type II diabetes (Schrauwen et al. 1999; Schrauwen et al. 2001; Y. J. Liu et al. 2005; 
Musa et al. 2011).  However, little is known about the mechanisms by which UCP3 
influences mitochondrial metabolism and contributes to energy homeostasis.  To better 
understand the physiological regulation of UCP3 function in mitochondrial metabolism 
we coupled immunoprecipitation methods with mass spectrometry to identify interacting 
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partners of UCP3.   The results showed that UCP3 associated with key mitochondrial 
metabolic enzymes involved in regulating fatty acid, glucose, and amino acid 
metabolism.  These diverse interactions suggest that UCP3 may play a key role in 
coordinating the different pathways of substrate metabolism to maintain energy 
homeostasis.   
 
4.2 Results 
Information about candidate interacting partners of a protein can help characterize 
functional protein relationships and reveal details about new biological networks.  Our 
lab has previously employed a yeast 2-hybrid assay to identify UCP3-interacting partners, 
however this type of screening inherently results in numerous false positives (Brückner et 
al. 2009). To circumvent this issue we employed a high-throughput immunoprecipitation-
mass spectrometry approach and identified ~82 target proteins that either indirectly or 
directly interact with UCP3 (Table 4.1).  Using the Scaffold Proteome Software, all 
targets were aligned to protein sequences in the NCBI database with protein and peptide 
probability thresholds set to 99% and 95%, respectively. The results were filtered for a 
minimum of 2 peptides with peak numbers representing how many unique peptides of a 
protein were identified within the sample.  We then eliminated protein targets that were 
likely non-specific interacting partners based on the criteria that peak numbers in the 
wild-type samples were less than or equal to peak numbers in the UCP3-/- samples.  In 
terms of the specificity of the immunoprecipitation pull down, a total of 42 peptides 
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unique to UCP3 were detected in our WT sample.  In contrast, there were no detectable 
peaks identified in our UCP3-/- group, thus suggesting that we were able to successfully 
purify UCP3 in our immunoprecipitation.    
 Consistent with the well-established association between UCP3 function and fatty 
acid metabolism, we show that UCP3 interacts with numerous enzymes that regulate 
mitochondrial fatty acid transport and oxidation.  Interestingly, the data also show that 
UCP3 interacts with key regulators of glucose and amino acid metabolism in the 
mitochondria.  Taken together, the data suggests that UCP3 could play a key role in 
coordinating glucose, amino acid, and lipid metabolism through its association with key 
metabolic enzymes.   
 
4.3 Discussion 
Although there is no consensus regarding the thermogenic capabilities of UCP3, it 
has been proposed that UCP3 may have an alternative function by which its activity 
contributes to whole-body energy metabolism.  The literature has shown that the 
beneficial metabolic effects of UCP3 overexpression in SKM are not limited to this 
particular tissue, and also protects against high fat diet-induced resistance in the liver 
(Choi et al. 2007).  Given the strong association between mitochondrial dysfunction and 
insulin resistance in SKM, this effect can likely be attributed to the influence that UCP3 
has on mitochondrial metabolism.  
Herein, we are the first to demonstrate that UCP3 interacts with key enzymes that 
regulate glucose and fatty acid metabolism.  Prevailing evidence indicates that efficient 
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fuel switching between fatty acid and glucose metabolism in response to the proper 
physiological and nutritional cues (i.e. transition from fasted to fed state) is crucial in 
maintaining energy homeostasis. Indeed, the importance of appropriate mitochondrial 
fuel selection is highlighted by studies showing that obese and diabetic patients fail to 
switch from fatty acid to glucose metabolism during the transition from a fasted to fed 
state (Kelley et al. 1999; Petersen et al. 2003; Befroy et al. 2007). According to Randle’s 
proposed glucose-fatty acid cycle, in a fasted state fatty acid metabolism in SKM is 
dominant and suppresses glucose uptake as a survival mechanism to prevent 
hypoglycemia(Randle et al. 1963). In this model, by-products of fatty acid β-oxidation, 
such as acetyl-CoA, act as an allosteric inhibitor of PDH.  Because pyruvate 
dehydrogenase is a key enzyme in regulating glycolytic flux, its inhibition results in a 
negative feedback of glucose uptake, which is especially critical during fasting when 
glucose should be spared for tissues that rely predominantly on this substrate, such as 
brain.  In contrast, this cycle can also be counter-regulated in a fed state where insulin-
stimulated glucose uptake increases flux through the TCA cycle and causes a surge in the 
mitochondrial efflux of citrate.  In the cytoplasm the citrate is converted to acetyl-CoA 
and then to the CPT1 inhibitor malonyl-CoA(Muoio 2014). In this model, efficient fuel 
switching from glucose to fatty acid metabolism and vice versa relies heavily on the 
gatekeeping function of PDH and CPT1. Given that our mass spectrometry data shows 
that UCP3 interacts with PDH and CPT1, it is possible that UCP3 plays an important role 
in coordinating the fuel switch from glucose and fatty acid metabolism in the transition 
from a fasted and fed state. Based on these findings, it is likely that UCP3 could play a 
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role in coordinating fatty acid and glucose metabolism through its interactions with key 
gatekeeping enzymes.  This idea is consistent with previous work showing that UCP3 
overexpression in SKM can influence fatty acid metabolism and improve glucose 
homeostasis (Choi et al. 2007).   
Our data also demonstrates that UCP3 interacts with numerous fatty acid 
metabolizing enzymes including acetyl-CoA acetyltransferase (Acat 1), medium chain 
specific acyl-CoA dehydrogenase (Acadm), subunits of trifunctional enzyme (Hadhb), 
short enoyl-CoA hydratase 1 (ECHs1), and enoyl-CoA delta isomerase 1 (ECI).  
Interestingly, ECI is a key enzyme involved in the complete degradation of unsaturated 
fatty acids, which have also been shown to be potent activators of UCP3 expression 
(Zackova et al. 2003; Thompson & D. Kim 2004).  If UCP3 activity is important in 
unsaturated fatty acid metabolism, it likely that UCP3 interacts with other enzymes 
involved in the degradation of these particular fatty acid species.  Indeed, our mass 
spectrometry data is consistent with our lab’s previous work showing that UCP3 interacts 
with the auxiliary unsaturated fatty acid metabolizing enzyme enoyl-CoA hydratase 1 
(ECH1), utilizing a yeast two-hybrid screen.  The reason as to why our mass 
spectrometry data did not detect ECH1 as an interacting partner could be due to 
optimization of our affinity purification using our lab’s custom-made UCP3 antibody.  
Regardless, our mass spectrometry data with our lab’s detailed characterization of the 
ECH1:UCP3 complex (next chapter), further supports the link between UCP3 activity 
and unsaturated fatty acid metabolism.   
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 In addition to fatty acids, mitochondrial degradation of amino acids also serves as 
an important alternative fuel source to glucose during prolonged fasting.  Proteolysis and 
amino acid catabolism is regulated in part through mitochondrial branched-chain ketoacid 
dehydrogenase complex (BKCD).  The first step in the degradation of branched chain 
amino acids is transanimation with α-ketoglutarate to form branched α-keto acids.  These 
products are then irreversibly metabolized by BCKD and fed in to the TCA cycle for 
complete degradation.  Interestingly, our mass spectrometry data shows that UCP3 also 
interacts with BCKD.  Although there is little information regarding UCP3 function and 
amino acid metabolism, clinical studies in a African American population carrying a 
missense allele mutation that leads to a truncated form of UCP3 showed that these 
patients reduced plasma concentrations of α-ketoglutarate in SKM of subjects fasted 
overnight (Fiehn et al. 2010).  Previous studies with this distinct population also showed 
a susceptibility in the development of severe obesity with whole-body lipid oxidation 
being significantly reduced (Argyropoulos et al. 1998).  
 Our findings, which demonstrate that UCP3 interacts with key enzymes involved 
in efficient mitochondrial substrate metabolism corresponds with the extensive literature 
regarding UCP3 in the protection against obesity-related diseases through mediation of 
whole-body energy balance. Future work is needed to characterize these interactions, as 
well as the complex mechanisms linking mitochondrial function and efficient fuel 




Table 4.1 Interacting partners of UCP3 identified by mass spectrometry 
Identified Proteins Accession Number WT UCP3 -/- 
Mitochondrial uncoupling protein 3 OS=Mus musculus GN=Ucp3 
PE=2 SV=1 sp|P56501|UCP3_MOUSE 42 0 
Isoform 2 of 2-oxoglutarate dehydrogenase, mitochondrial OS=Mus 
musculus GN=Ogdh 
sp|Q60597-2|ODO1_MOUSE 
(+3) 9 0 
ATP synthase subunit O, mitochondrial OS=Mus musculus GN=Atp5o 
PE=1 SV=1 sp|Q9DB20|ATPO_MOUSE 15 0 
Trifunctional enzyme subunit beta, mitochondrial OS=Mus musculus 
GN=Hadhb PE=1 SV=1 sp|Q99JY0|ECHB_MOUSE 12 0 
Carnitine O-palmitoyltransferase 1, muscle isoform OS=Mus musculus 
GN=Cpt1b PE=2 SV=1 sp|Q924X2|CPT1B_MOUSE 11 0 
Acetyl-CoA acetyltransferase, mitochondrial OS=Mus musculus 
GN=Acat1 PE=1 SV=1 sp|Q8QZT1|THIL_MOUSE 8 0 
60 kDa heat shock protein, mitochondrial OS=Mus musculus 
GN=Hspd1 PE=1 SV=1 sp|P63038|CH60_MOUSE 5 0 
Dihydrolipoyl dehydrogenase, mitochondrial OS=Mus musculus 
GN=Dld PE=1 SV=2 sp|O08749|DLDH_MOUSE 9 0 
Myosin light chain 1/3, skeletal muscle isoform OS=Mus musculus 
GN=Myl1 PE=1 SV=2 
sp|P05977|MYL1_MOUSE 
(+1) 6 0 
ATP synthase gamma chain OS=Mus musculus GN=Atp5c1 PE=3 
SV=1 tr|A2AKU9|A2AKU9_MOUSE 7 0 
Histone H1.4 OS=Mus musculus GN=Hist1h1e PE=1 SV=2 sp|P43274|H14_MOUSE 2 0 
Electron transfer flavoprotein subunit beta OS=Mus musculus GN=Etfb 
PE=1 SV=3 sp|Q9DCW4|ETFB_MOUSE 4 0 
Beta-globin OS=Mus musculus GN=Hbb-b1 PE=3 SV=1 
tr|A8DUK4|A8DUK4_MOUSE 
(+1) 7 0 
Isoform 2 of Sacsin OS=Mus musculus GN=Sacs 
sp|Q9JLC8-2|SACS_MOUSE-
R (+3) 3 0 
Malate dehydrogenase, mitochondrial OS=Mus musculus GN=Mdh2 
PE=1 SV=3 sp|P08249|MDHM_MOUSE 4 0 
AMP deaminase 1 OS=Mus musculus GN=Ampd1 PE=2 SV=1 
sp|Q3V1D3|AMPD1_MOUSE 
(+2) 4 0 
Histone H2B type 1-F/J/L OS=Mus musculus GN=Hist1h2bf PE=1 
SV=2 
sp|P10853|H2B1F_MOUSE 
(+12) 4 0 
Thioredoxin-dependent peroxide reductase, mitochondrial OS=Mus 
musculus GN=Prdx3 PE=1 SV=1 sp|P20108|PRDX3_MOUSE 4 0 
Lipoamide acyltransferase component of branched-chain alpha-keto 
acid dehydrogenase complex, mitochondrial OS=Mus musculus 
GN=Dbt PE=2 SV=2 sp|P53395|ODB2_MOUSE 5 0 
Glycogen [starch] synthase, muscle OS=Mus musculus GN=Gys1 PE=1 
SV=2 
sp|Q9Z1E4|GYS1_MOUSE 
(+1) 5 0 
Isocitrate dehydrogenase [NADP], mitochondrial OS=Mus musculus 
GN=Idh2 PE=1 SV=3 sp|P54071|IDHP_MOUSE 5 0 
Ig gamma-2A chain C region secreted form OS=Mus musculus PE=1 
SV=1 
sp|P01864|GCAB_MOUSE 
(+1) 3 0 
GrpE protein homolog 1, mitochondrial OS=Mus musculus GN=Grpel1 
PE=1 SV=1 sp|Q99LP6|GRPE1_MOUSE 3 0 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial 
OS=Mus musculus GN=Ndufs3 PE=1 SV=2 sp|Q9DCT2|NDUS3_MOUSE 3 0 
Aldehyde dehydrogenase, mitochondrial OS=Mus musculus GN=Aldh2 
PE=1 SV=1 sp|P47738|ALDH2_MOUSE 4 0 
Chaperone activity of bc1 complex-like, mitochondrial OS=Mus 
musculus GN=Adck3 PE=2 SV=2 
sp|Q60936|ADCK3_MOUSE 





Table 4.1 (continued) 
 
MCG140437, isoform CRA_d OS=Mus musculus GN=Myh2 PE=4 
SV=1 tr|G3UW82|G3UW82_MOUSE 4 0 
ATP synthase subunit d, mitochondrial OS=Mus musculus GN=Atp5h 
PE=1 SV=3 
sp|Q9DCX2|ATP5H_MOUSE 
(+1) 5 0 
Ubiquitin-protein ligase E3A OS=Mus musculus GN=Ube3a PE=2 
SV=1 
sp|O08759|UBE3A_MOUSE 
(+1) 0 0 
Isoform 2 of DnaJ homolog subfamily A member 3, mitochondrial 
OS=Mus musculus GN=Dnaja3 
sp|Q99M87-
2|DNJA3_MOUSE (+2) 2 0 
Isoform Cytoplasmic of Fumarate hydratase, mitochondrial OS=Mus 
musculus GN=Fh 
sp|P97807-2|FUMH_MOUSE 
(+1) 3 0 
Glycogen phosphorylase, muscle form OS=Mus musculus GN=Pygm 
PE=1 SV=3 
sp|Q9WUB3|PYGM_MOUSE 
(+1) 3 0 
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 
OS=Mus musculus GN=Acadm PE=1 SV=1 sp|P45952|ACADM_MOUSE 3 0 
Aspartate-beta-hydroxylase OS=Mus musculus GN=Asph PE=4 SV=1 tr|A2AL78|A2AL78_MOUSE 4 0 
Enoyl-CoA hydratase, mitochondrial OS=Mus musculus GN=Echs1 
PE=1 SV=1 sp|Q8BH95|ECHM_MOUSE 3 0 
60S acidic ribosomal protein P0 OS=Mus musculus GN=Rplp0 PE=1 
SV=3 
sp|P14869|RLA0_MOUSE 
(+1) 3 0 
Triosephosphate isomerase OS=Mus musculus GN=Tpi1 PE=3 SV=1 
tr|H7BXC3|H7BXC3_MOUSE 
(+1) 4 0 
Alpha globin 1 OS=Mus musculus GN=Hba-a1 PE=2 SV=1 tr|Q91VB8|Q91VB8_MOUSE 4 0 
Tubulin alpha-1B chain OS=Mus musculus GN=Tuba1b PE=1 SV=2 
sp|P05213|TBA1B_MOUSE 
(+1) 2 0 
[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial 
OS=Mus musculus GN=Pdk4 PE=2 SV=1 sp|O70571|PDK4_MOUSE 3 0 
Tropomyosin beta chain OS=Mus musculus GN=Tpm2 PE=1 SV=1 
sp|P58774|TPM2_MOUSE 
(+1) 3 0 
Tubulin beta-4B chain OS=Mus musculus GN=Tubb4b PE=1 SV=1 
sp|P68372|TBB4B_MOUSE 
(+1) 3 0 
Nuclear pore membrane glycoprotein 210 OS=Mus musculus 
GN=Nup210 PE=1 SV=2 sp|Q9QY81|PO210_MOUSE-R 2 0 
Fumarylacetoacetate hydrolase domain-containing protein 2A OS=Mus 
musculus GN=Fahd2 PE=1 SV=1 sp|Q3TC72|FAHD2_MOUSE 2 0 
Isoform 2 of Neuralized-like protein 4 OS=Mus musculus GN=Neurl4 
sp|Q5NCX5-
2|NEUL4_MOUSE (+3) 2 0 
Hexaprenyldihydroxybenzoate methyltransferase, mitochondrial 
OS=Mus musculus GN=Coq3 PE=2 SV=1 sp|Q8BMS4|COQ3_MOUSE 2 0 
Mitochondrial 2-oxoglutarate/malate carrier protein OS=Mus musculus 
GN=Slc25a11 PE=1 SV=3 
sp|Q9CR62|M2OM_MOUSE 
(+1) 2 0 
Protein Pcdhb12 OS=Mus musculus GN=Pcdhb12 PE=3 SV=1 tr|F6V243|F6V243_MOUSE 2 0 
Myosin-4 OS=Mus musculus GN=Myh4 PE=1 SV=1 sp|Q5SX39|MYH4_MOUSE 30 2 
Isoform 2 of Ig gamma-2B chain C region OS=Mus musculus GN=Igh-
3 
sp|P01867-2|IGG2B_MOUSE 
(+1) 4 3 
Tripartite motif-containing protein 72 OS=Mus musculus GN=Trim72 
PE=1 SV=1 sp|Q1XH17|TRI72_MOUSE 13 3 
Creatine kinase S-type, mitochondrial OS=Mus musculus GN=Ckmt2 
PE=1 SV=1 sp|Q6P8J7|KCRS_MOUSE 10 3 
Isocitrate dehydrogenase [NAD] subunit gamma 1, mitochondrial 
OS=Mus musculus GN=Idh3g PE=1 SV=1 sp|P70404|IDHG1_MOUSE 9 3 




Table 4.1 (continued) 
 
Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial 
OS=Mus musculus GN=Sucla2 PE=1 SV=2 sp|Q9Z2I9|SUCB1_MOUSE 27 4 
Trifunctional enzyme subunit alpha, mitochondrial OS=Mus musculus 
GN=Hadha PE=1 SV=1 sp|Q8BMS1|ECHA_MOUSE 21 4 
Calcium-binding mitochondrial carrier protein Aralar1 OS=Mus 
musculus GN=Slc25a12 PE=1 SV=1 sp|Q8BH59|CMC1_MOUSE 14 4 
Elongation factor Tu, mitochondrial OS=Mus musculus GN=Tufm 
PE=1 SV=1 
sp|Q8BFR5|EFTU_MOUSE 
(+1) 20 5 
Ryanodine receptor 1 OS=Mus musculus GN=Ryr1 PE=1 SV=1 
sp|E9PZQ0|RYR1_MOUSE 
(+1) 16 5 
Glycerol-3-phosphate dehydrogenase, mitochondrial OS=Mus musculus 
GN=Gpd2 PE=1 SV=2 
sp|Q64521|GPDM_MOUSE 
(+1) 13 5 
Enoyl-CoA delta isomerase 1, mitochondrial OS=Mus musculus 
GN=Eci1 PE=2 SV=2 sp|P42125|ECI1_MOUSE 10 5 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 
OS=Mus musculus GN=Ndufa4 PE=1 SV=2 sp|Q62425|NDUA4_MOUSE 10 6 
Glyceraldehyde-3-phosphate dehydrogenase OS=Mus musculus 
GN=Gapdh PE=1 SV=2 sp|P16858|G3P_MOUSE 15 7 
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 
OS=Mus musculus GN=Acadvl PE=1 SV=3 sp|P50544|ACADV_MOUSE 45 8 
Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial 
OS=Mus musculus GN=Suclg1 PE=1 SV=4 sp|Q9WUM5|SUCA_MOUSE 16 8 
Complement C1q subcomponent subunit C OS=Mus musculus 
GN=C1qc PE=2 SV=2 sp|Q02105|C1QC_MOUSE 11 8 
Actin, alpha skeletal muscle OS=Mus musculus GN=Acta1 PE=1 SV=1 sp|P68134|ACTS_MOUSE 18 9 
Isoform 2 of Sarcalumenin OS=Mus musculus GN=Srl 
sp|Q7TQ48-2|SRCA_MOUSE 
(+1) 15 10 
Electron transfer flavoprotein subunit alpha, mitochondrial OS=Mus 
musculus GN=Etfa PE=1 SV=2 sp|Q99LC5|ETFA_MOUSE 18 11 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial OS=Mus musculus GN=Sdha PE=1 SV=1 sp|Q8K2B3|DHSA_MOUSE 28 12 
Complement C1q subcomponent subunit A OS=Mus musculus 
GN=C1qa PE=1 SV=2 sp|P98086|C1QA_MOUSE 18 12 
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 
OS=Mus musculus GN=Pdhb PE=1 SV=1 sp|Q9D051|ODPB_MOUSE 22 13 
3-ketoacyl-CoA thiolase, mitochondrial OS=Mus musculus GN=Acaa2 
PE=1 SV=3 sp|Q8BWT1|THIM_MOUSE 22 13 
Calsequestrin-1 OS=Mus musculus GN=Casq1 PE=2 SV=3 sp|O09165|CASQ1_MOUSE 20 16 
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial OS=Mus 
musculus GN=Idh3a PE=1 SV=1 sp|Q9D6R2|IDH3A_MOUSE 22 17 
Isocitrate dehydrogenase 3 (NAD+) beta OS=Mus musculus GN=Idh3b 
PE=2 SV=1 tr|Q91VA7|Q91VA7_MOUSE 38 20 
Aconitate hydratase, mitochondrial OS=Mus musculus GN=Aco2 PE=1 
SV=1 sp|Q99KI0|ACON_MOUSE 80 22 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial OS=Mus musculus GN=Dlat 
PE=1 SV=2 sp|Q8BMF4|ODP2_MOUSE 27 23 
ADP/ATP translocase 1 OS=Mus musculus GN=Slc25a4 PE=1 SV=4 sp|P48962|ADT1_MOUSE 49 29 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 OS=Mus 
musculus GN=Atp2a1 PE=2 SV=1 sp|Q8R429|AT2A1_MOUSE 134 69 
ATP synthase subunit alpha, mitochondrial OS=Mus musculus 
GN=Atp5a1 PE=1 SV=1 sp|Q03265|ATPA_MOUSE 146 73 
ATP synthase subunit beta, mitochondrial OS=Mus musculus 





Chapter 5: The novel interaction between UCP3 and ECH1 
 
5.1 Introduction 
  The interplay between mitochondrial bioenergetics and fatty acid metabolism has 
been intricately linked to the pathophysiology of obesity and –related metabolic 
complications. The observation that the accumulation of toxic intramuscular lipid 
intermediates including diacylglycerol and ceramide negatively correlates with insulin 
sensitivity, led researchers to believe that diminished mitochondrial fatty acid oxidation is 
the underlying mechanism of obesity-related complications (Krssak et al. 1998; Pan et al. 
1997; Roden et al. 1996; Boden 2011).  However, therapeutic approaches that focus on 
increasing fatty acid metabolism alone as a means to relieve mitochondrial congestion 
and counteract the effects of lipotoxicity have been met with conflicting results. A new 
theory that has emerged in recent years is centered on the premise of relieving nutrient 
overload and restoring energy dysregulation through targeting mitochondrial 
bioenergetics.  In this model, nutrient overload induces an energetic imbalance where the 
rate of fatty acid catabolism exceeds the capacity of the ETC.  Therefore, adjusting the 
flux rate through β-oxidation in the absence of a corresponding change in energy 
utilization will just impinge additional pressure on mitochondrial respiration (Muoio & 
Neufer 2012).  Thus, strategies that coordinate an increase in the rates of fatty acid 
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oxidation with energy demand as a means to relieve mitochondrial overload are 
promising therapeutic strategies for combating metabolic disease.  
 There are several studies to support that UCP3 functions to regulate lipid 
metabolism and lower metabolic efficiency. First, being the induction of UCP3 
expression in physiological states where fatty acid levels are high, such as high fat 
feeding and fasting, which suggests that UCP3 is important in mediating lipid handling 
and preventing mitochondrial overload (Bézaire et al. 2001) (Felipe et al. 2003; Chou et 
al. 2001) and fasting (Samec et al. 1999). Additionally, transgenic mice that overexpress 
UCP3 in SKM at physiological levels were found to be lean despite being hyperphagic 
(Clapham et al. 2000), and  showed lower levels of intramuscular triacylglycerol stores 
(Bézaire et al. 2005).  From these findings, it has been suggested that in conditions where 
fatty acid supply exceeds the oxidation capacity of SKM, up-regulation of UCP3 
expression facilitates an overflow pathway to increase the fatty acid oxidation capacity of 
SKM. Although, there are several studies to implicate UCP3 involvement in regulating 
mitochondrial fatty acid transport and metabolism in certain physiological contexts the 
regulatory mechanisms are unclear.  
This study sheds light on the link between UCP3 function and mitochondrial fatty 
acid metabolism in SKM mitochondria. As discussed earlier, our lab has previously 
shown that UCP3 directly interacts with the auxiliary, unsaturated fatty acid metabolizing 
enzyme enoyl CoA hydratase 1 (ECH1). Unsaturated fatty acids with double bonds in the 
odd position must have these double bonds isomerized to even positions to allow their 
complete oxidation.  This is accomplished through either the isomerase dependent 
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pathway or the reductase dependent pathway. In the reductase-pathway, ECH1 catalyzes 
the isomerization of the 3-trans, 5–cis dienoyl-CoA substrate to the 2-trans, 4-trans 
dienoyl-CoA substrate (Filppula 1998; Luthria et al. 1995).  Although little is known 
about the physiological relevance of ECH1, it has been proposed that flux through the 
reductase-dependent pathway is important in preventing the depletion of free coenzyme 
A, thus protecting mitochondrial oxidative function and maintaining energy balance 
(Shoukry & Schulz 1998).  It has been shown that bacteria that do not express ECH1 rely 
upon fatty acid export to defend against the accumulation of unmetabolizeable enoyl-
CoA derivatives which could stall β-oxidation (Ren et al. 2004).  Additionally, fatty acid 
levels are significantly increased after ECH1-knockdown in C. elegans roundworms 
compared to wild-type.   Furthermore, studies in mice lacking 2,4-dienoyl-CoA reductase 
(DECR), another auxiliary enzyme involved in unsaturated fatty acid oxidation, showed a 
compromised thermoregulatory response when challenged by fasting and cold exposure 
(Miinalainen et al. 2009).  Together, these studies indicate that the auxiliary enzymes 
involved in the complete breakdown of unsaturated fatty acids are critical in that 
adaptation to metabolic stress (e.g. fasting) by maintaining balanced fatty acid and energy 
metabolism.  
 Herein, we demonstrate a mechanism by which UCP3 mediates fatty acid 
oxidation and mitochondrial metabolism via its interaction with the auxiliary unsaturated 
fatty acid metabolizing enzyme ECH1.  The physiological relevance of this work is 
supported by observations that UCP3 and ECH1 directly interact at endogenous 
concentrations in SKM to enhance uncoupled respiration and unsaturated fatty acid 
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oxidation.  With the use of UCP3 and ECH1-knockout mouse models, our work 
demonstrates that both proteins are important regulators of cold-induced thermogenesis 
during periods of metabolic stress.  
5.2 Results 
5.2.1 Identifying the interaction between UCP3 and ECH1   
The endogenous function(s) of ECH1 in a physiological context are unclear.  
Interestingly, ECH1 exhibited an overlapping protein expression profile with UCP3 in 
highly metabolic tissues including BAT, SKM, and heart (HRT) (Figure 5.1 A). Previous 
work in our lab has shown that ECH1 and UCP3 interact when overexpressed, and also 
form a direct complex with each other in vitro. Considering the substantial role of SKM 
in whole body energy metabolism, we then tested whether the ECH1:UCP3 complex 
could be detected in differentiated C2C12 myotubes.  C2C12s mouse myoblasts were 
subjected to low serum-induced differentiation (2% equine serum) to induce UCP3 
mRNA and protein expression (Figure 5.1 C, upper blot, days 2-6) as previously shown 
(Nagase et al. 2001; Solanes et al. 2000; Son et al. 2001).  Interestingly, that data showed 
that endogenous ECH1 mRNA and protein levels did not change upon differentiation 
(Figure  5.1 B).   Using lysates from differentiated myotubes, we found that endogenous 
ECH1 could be detected when immunoprecipitated with anti-UCP3, but not with rabbit 





Figure 5.1 Characterizing the interaction between ECH1 and UCP3 
(A) ECH1 and UCP3 protein expression profiles in mitochondrial lysates isolated from 
brown adipose tissue (BAT), SKM (SKM), heart (HRT), and liver (LVR) tissues (n=5). 
(B-C) Endogenous mRNA and protein expression levels of ECH1 and UCP3 in 
differentiating mouse myoblasts C2C12s. (D) Mitochondrial lysates isolated from 
myotubes were immunoprecipitated with anti-UCP3 or negative control IgG.  Co-
































































An interesting characteristic of ECH1 is that it contains both mitochondrial and 
peroxisomal targeting sequences that flank the catalytic and trimerization domains 
(Modis et al. 1998; Zhang et al. 2001).  Previous studies investigating ECH1 function 
have primarily focused on its characterization in liver and heart therefore its subcellular 
localization in SKM has not been defined. To examine whether ECH1 localizes 
predominantly to the mitochondria or peroxisomes, immunocytochemistry was 
performed on C2C12 myocytes that were co-transfected with ECH1-Myc and either 
Mito-GFP or the empty vector control plasmid (Figure 5.2 A). Pearson’s correlation 
coefficient was calculated to quantify ECH1’s subcellular localization, and revealed that 
ECH1 localizes predominantly to mitochondria based on the co-localization of ECH1’s 
immunofluorescent stain with Mito-GFP (Figure 5.2 B).  Endogenous staining of catalase 
was used as a peroxisomal marker.   
5.2.2 Fatty acid regulation of ECH1 and UCP3 
After confirming that ECH1 localizes primarily to mitochondria and that UCP3 
endogenously interacts in C2C12 myotubes, we then focused on defining the biochemical 
and physiological factors that regulate ECH1 and UCP3 complex formation. We 
generated Myc-tagged ECH1 catalytic mutants to address whether the mutants could be 
co-immunoprecipitated with UCP3-V5 in lysates extracted from co-transfected cells 
(Figure 5.3 A).  According to structural and mechanistic studies of ECH1, the aspartic 
acid 204 (D204) and glutamic acid 196 (E196) residues located in the active site of ECH1 




Figure 5.2 Subcellular localization of ECH1 in C2C12 myoblasts   
(A) Representative immunocytochemistry images of C2C12 myoblasts co-transfected 
with ECH1-Myc and either the GFP fusion protein containing a mitochondrial targeting 
sequence (Mito-GFP, mitochondrial marker) or empty vector control.  Cells were 
incubated with primary antibodies anti-Myc (ECH1-Myc) and anti-catalase (peroxisome 
marker), followed by incubation with corresponding fluorescent secondary antibodies 
anti-mouse (red, mECH1-Myc) and anti-rabbit (green, bottom panel, catalase).  (B) 
Pearson’s correlation coefficient for co-localization of ECH1-Myc (red) and Mito-GFP or 
catalase (green) (n= 6-7 cells).  Data are expressed as mean ± SEM from three 

































Figure 5.3 Fatty acid regulation of the ECH1 and UCP3 interaction 
(A) Lysates were immunoprecipitated with either IgG or anti-Myc from cells co-
transfected with UCP3-V5 and either ECH1-Myc or the Myc-tagged ECH1 catalytic 
mutant constructs (D204N-Myc and E196Q-Myc).  To rule out any effects independent 
of catalytic activity we generated an ECH1 mutant that has been previously shown to 
retain enzymatic activity (D176N-Myc) and the ECH1 double mutant that re-introduced 
the E196Q catalytic mutation (D176N/E196Q-Myc). Co-immunoprecipitated UCP3-V5 
was detected by immunoblotting with anti-V5. (B) Co-transfected cells were treated for 
18hrs with either vehicle (lane 1-2) or 75 µM etomoxir the CPT1 inhibitor. Co-
immunoprecipitations were performed as previously described.  For densitometry 
precipitated UCP3-V5 (top panel) was normalized to pull down of ECH1-Myc. Data 
represent means ± SEM from 3 independent experiments. ***p< 0.001. (C)  Protein 
expression levels of UCP3 and ECH1 are both elevated in SKM of wild type mice fed 
high fat diet (60% kCal).  For densitometry ECH1 and UCP3 protein expression was 
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also located in the active site of ECH1, but is shown to have little effect on catalytic 
activity (Zhang et al. 2001).  Both Myc-tagged ECH1 catalytic mutants D204N-Myc and 
E196-Myc, demonstrated a diminished interaction with UCP3-V5 in comparison to 
ECH1-Myc.  Interestingly, the ECH1 mutant D176N-Myc, that still possessed catalytic 
activity, did not have the same attenuated effect on complex formation with UCP3-V5. 
Furthermore, the double mutant construct D176N/E196Q-Myc was not able to interact 
with UCP3-V5 to the same extent as ECH1-Myc, thus highlighting the importance of 
ECH1 catalytic activity in complex formation with UCP3. 
If ECH1 catalytic activity greatly affects ECH1 and UCP3 complex formation, 
then it is possible that flux through the mitochondrial pathways of fatty acid metabolism 
may play an important role in regulating the ECH1:UCP3 interaction.  To test this idea, 
we blocked mitochondrial fatty acid import by inhibiting the key mitochondrial fatty acid 
transporter, carnitine palmitoyl transferase I (CPT1) with the drug etomoxir.  Co-
immunoprecipitation experiments were performed in lysates extracted from HEK293T 
cells previously co-transfected with UCP3-V5 and ECH1-Myc, and treated with 75µM 
etomoxir. Densitometry analyses of immunoblots detecting the amount of UCP3-V5 co-
immunoprecipitated with ECH1-Myc showed a ~2 fold decrease in complex formation 
with the etomoxir treated cells compared to vehicle treated (Figure 5.3 B).  
5.2.3 Functional implications of ECH1:UCP3 complex in SKM metabolism 
Given our previous data indicating that fatty acids play a key role in stimulating 
ECH1:UCP3 complex formation, we predicted that this interaction could be particularly 
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important in physiologically relevant conditions that require high levels of fatty acid 
metabolism (e.g. fasting and high fat feeding).  Indeed, we observed a ~1.5 and 2 fold 
increase in ECH1 and UCP3 protein expression levels, respectively, in isolated SKM 
mitochondria from mice fed high-fat diets for 6 weeks (Figure 5.4A). In order to 
characterize the functional influence of the ECH1:UCP3 complex on mitochondrial 
metabolism in SKM we utilized the Precision Lenti-ORF plasmids (pLOC) to generate 
stable cell lines in C2C12 myoblasts that either overexpresses ECH1 (C2C12-ECH1) or 
empty vector, pLOC (C2C12-EV).  Stables colonies of both cell lines were selected and 
densitometry analyses confirmed protein overexpression of ECH1 in the C212-ECH1 cell 
lines at physiological levels (Figure 5.4 B) similar to the induction of ECH1 expression in 
SKM of mice fed high fat diets (Figure 5.4 A).  Considering that UCP3 function is 
closely tied to fatty acid metabolism, if ECH1 forms a direct complex with UCP3 in the 
presence of fatty acids it is possible that complex formation could regulate UCP3 activity 
and thus enhance uncoupled respiration.  To investigate this notion we transfected UCP3-
V5 in to our stable cell lines C2C12-ECH1 and -EV and measured uncoupled respiration 
using a fiber-optic fluorescence oxygen monitoring system. As shown in Figure 5.4 C 
oligomycin-induced uncoupled respiration was higher in cells overexpressing ECH1 and 
UCP3-V5 compared to cells expressing UCP3-V5 alone.  We then set out to examine the 
consequences of the ECH1:UCP3 complex formation on ECH1-dependent metabolism of 




Figure 5.4 Functional implications of ECH1:UCP3 complex on fatty acid 
metabolism and uncoupled respiration 
(A) Protein expression levels of UCP3 and ECH1 are both elevated in SKM of wild type 
mice fed high fat diet (60% kCal).  For densitometry ECH1 and UCP3 protein expression 
was normalized to mitofusin 2.  Data expressed as mean ± SEM (n=6). *p< 0.05. (B) 
Lentiviral overexpression of ECH1 in C2C12.   For lentiviral transduction, C2C12s were 
incubated with lentiviral particles containing either the empty vector Precision Lenti-ORF 
plasmid (pLOC) or pLOC-ECH1 construct. Stable colonies of C2C12s expressing empty 
vector pLOC (C2C12-EV) or pLOC-ECH1 (C2C12-ECH1) were selected with 
blasticidin and grown up.  Densitometry analyses of immunoblots detecting ECH1 
protein expression normalized to mitofusin 2 confirmed stable overexpression of ECH1 
in C2C12-ECH1 lines. (C) ECH1 expression enhances uncoupled respiration.  C2C12-
EV and C2C12-ECH1 cells were transfected with UCP3-V5 (UCP3) or empty vector 
(Ctrl). Uncoupled respiration was normalized to basal respiration rates.  (D) ECH1 and 
UCP3 expression increased unsaturated fatty acid oxidation.  Data are expressed as mean 




































stable cell lines transfected with UCP3-V5.  Consistent with previous observations, 
UCP3 expression alone led to a slight increase in oleate metabolism (Figure 5.4 D).  
Interestingly, ECH1 and UCP3 overexpression led to a synergistic increase in oleate 
oxidation.  
5.2.4 Characterization of the ECH-/- mouse model 
 In order to further investigate the role of physiological relevance of ECH1 in 
whole body energy metabolism a global ECH1 knockout mouse model (ECH1-/-) utilizing 
a zinc finger nucleases (ZFNs)-based genomic approach. Engineered ZFNs have been 
successfully employed to generate gene knockout models by introducing sequence-
specific double strand breaks that lead to nonhomologous end joining (NHEJ)-mediated 
deletions or insertions at the target site (Cui et al. 2011).  The custom made ECH1-ZFNs 
compromised of a DNA binding domain, targeted to exon 3 of the mouse ECH1 gene 
located on chromosome 7, was fused to a Fok I nuclease domain. Genomic PCR 
confirmed ZFN-mediated mutations (Figure 5.5 A).  Two founder lines were then 
selected (line 3 and ll) based on sequence analysis of verified targeted ZFN-induced 
deletions or insertions (Figure 5.6 B-C).  Analyses of ECH1 expression by western blot 
confirmed a complete loss of ECH1 expression in SKM, BAT, and HRT in both founder 
lines (Figure 5.6 D, line 3 data not shown). The data presented in the following 
experiments were performed with the fully back-crossed line 11-founder line (ECH1-/-). 





Figure 5.5 Generation of the ECH-knockout mouse model 
(A) Schematic of zinc finger nucleases (ZFNs) target site.  Nuclease cleavage domain 
indicated by Fok I site.  (B) PCR analysis of ZFN-induced mutations. Wild-type (WT) 
was included as a positive control Lane 3 and 11 represent the selected founder lines. (C) 
Sequences of ZFN-induced mutations in founder lines. (D) ECH1 protein expression in 













Founder line ZFN-mediated mutation 
Line 3 ATATC----------------- (31bp)-------------------TCCGGTGCAGGAA 
GGTGT-----------------------(528bp)--------------------------TTGTA 
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Similar to UCP3, it has been proposed that ECH1 may play a crucial role in the 
protection against lipid overload in conditions of high metabolic stress where fatty acids 
serves as the primary source of energy. Given that fatty acid metabolism and transport is 
essential in driving cold-induced thermogenesis, it is not surprising that the most 
common phenotype seen with whole body knockout mouse models of different fatty acid  
metabolizing enzymes is severe cold intolerance with prior fasting (Miinalainen et al. 
2009; Janssen & Stoffel 2002). In order to explore the physiological relevance of ECH1 
and UCP3 in conditions of metabolic stress, we utilized the UCP3 and ECH1 knockout 
mouse models to investigate whether these mice would have similar thermogenic 
phenotypes in response to prolonged periods of fasting.  
Even though UCP3-/- mice do not exhibit susceptibility to cold exposure or 
obesity, there is significant evidence to support the role of UCP3 in maintaining energy 
balance in metabolically challenging conditions that require higher rates of fatty acid 
oxidation.  Indeed, experiments demonstrating that fasted UCP3-/- mice exhibited 
impaired rates of fatty acid oxidation along with elevated levels of lipid accumulation in 
the matrix, suggest that UCP3 is necessary for mitochondrial adaptation to fasting 
(Seifert et al. 2008). Interestingly, following an 18hrs fasting period we found that the 
fasted UCP3-/- mice were more sensitive to cold after 6hrs compared to the wild-type 
group (Figure 5.6).  
We then focused on characterizing the role of ECH1 in metabolic stress.  Similar 
to the wild-type, the fed ECH1-/- mice showed a slight decrease in body temperature 






Figure 5.6 UCP3 is important in maintaining core body temperature in conditions of 
severe metabolic stress 
Data represents the core body temperatures of individual UCP3-/- and C57BL/6J mice 
following 6hr cold exposure (4°C).   Fasted groups underwent 18hr fasting challenge 






Figure 5.7 Thermogenesis in ECH1-/- mice in conditions of severe metabolic stress 
(A) Body temperatures of WT and ECH1 -/- mice following 18hr fast and 3hr cold 
challenge at 4°C.  * p< 0.05, statistical significance was was detected by two way 
analysis of variance (ANOVA) followed by Tukey’s post hoc test. (B) Body weights of 
WT and ECH1-/- before (fed) and after 18hr fast (fasted) (n=4-5). *p< 0.05, statistical 
significance was detected by student’s t test  (C) mRNA expression levels of canonical 
cold-induced genes (n=4-5).   
Data are expressed as +/- SEM and representative of experiments performed with the 










Fasted ECH1-/- mice were unable to maintain core body temperature during acute cold 
exposure at 4°C, reaching critical hypothermia (<25°C) after 3 hours. Interestingly, the 
body weights of the wild-type and ECH1-/- mice were not different in the fasted and fed 
groups, thus indicating that the thermogenic phenotype seen in the ECH1-/- mice was 
independent of any differences in body weight following fasting (Figure 5.7 B). To 
further characterize the thermogenic phenotype in the ECH1-/- mice, we focused on 
determining whether this effect was due to impaired adrenergic stimulation of BAT 
thermogenesis by examining the expression of canonical cold-induced thermogenic 
genes.  Compared to the wild-type group we found that the ECH1-/- mice did not exhibit a 
difference in mRNA expression levels of cold-induced BAT thermogenic genes including 
UCP1 and Dio2 (Figure 5.7 C). These results suggest that the signaling downstream of 
adrenergic stimulation of BAT in response to cold exposure is intact in the ECH1-/- mice 
and is not likely contributing to the severe cold-intolerant phenotype.  
5.2.5 Characterization of ECH1 in brown adipose tissue 
 Given that BAT is another important site of regulated energy expenditure and 
inducible proton leak, we then focused on characterizing the physiological function of 
ECH1 in BAT.  Considering that UCP1 and UCP3 are both expressed in BAT and shares 
57% amino acid sequence homology (Vidal-Puig et al. 1997), we reasoned that ECH1 
could interact with both UCP-homologues in BAT to regulate whole-body metabolism.  






Figure 5.8 Characterization of ECH1 in BAT 
(A) ECH1 interacts with UCP1 and UCP1 in BAT.  Co-immunoprecipitating proteins 
were detected by immunoblotting with either anti-UCP3 or anti-UCP1.  (B) Protein 
expression levels of ECH1, UCP3, and UCP1 of wild type mice fed high fat diet (60% 
kCal).  For densitometry ECH1, UCP3 protein expression was normalized to mitofusin 2.  































BAT showed that ECH1 interacts with UCP1 and UCP3 at endogenous levels (Figure 5.8 
A).  
As previously discussed, we have shown that UCP3 and ECH1 protein expression 
is induced in SKM in response to high fat feeding, thus implicating the physiological 
relevance of ECH1:UCP3 complex formation in fatty acid-induced pathologies.  In 
contrast, we did not see a similar pattern in BAT with UCP1 and UCP3 protein 
expression levels remaining relatively unchanged, despite a statistically significant 
increase (p<0.0001) in ECH1 expression with mice fed high fat diets for 6 weeks (Figure 
5.8 B).  The lack of early induction of UCP1 and UCP3 protein expression could suggest 
that BAT uncoupling activity is not relevant at the early stages of obesity.  Regardless, it 
is clear from this data that regulation of complex formation of ECH1 with UCP1 and/or 
UCP3 in BAT is different in SKM.   
 
5.3 Discussion 
 There is considerable evidence to support that UCP3 has the ability to lower 
metabolic efficiency and facilitate higher rates of fatty acid metabolism in order to 
protect SKM mitochondria from nutrient overload, but only when activated in certain 
physiological contexts.  Fatty acids have been implicated as potent activators of UCP 
function (Jiménez-Jiménez et al. 2006; Skulachev 1999; Hagen & Lowell 2000), however 
significant debate exists regarding the mechanisms by which fatty acids activate UCP3, 
and by which UCP3 regulates fatty acid metabolism. Our work demonstrating that the 
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auxiliary unsaturated fatty acid metabolizing enzyme ECH1 interacts with UCP3 in the 
mitochondrial matrix, at endogenous levels, supports a mechanism by which UCP3 can 
coordinate an increase in fatty acid metabolism with energy expenditure through 
uncoupling.  Importantly, we also demonstrate that UCP3 and ECH1 are both important 
in facilitating an adaptive response to metabolic stress, and that complex formation 
between these proteins is key in regulating a thermogenic response to acute cold exposure 
in a fasted state.   
 The characterization of the ECH1:UCP3 complex sheds new light on how the 
specific metabolism of polyunsaturated fatty acids with odd-numbered double bonds 
contributes to mitochondrial energy balance.  ECH1 is a unique enzyme in that it 
demonstrates dual-organelle distribution to the peroxisomes and mitochondria in 
mammalian cells in liver and heart.  The enzyme contains a known type I peroxisomal 
targeting sequence (SKL) in its C-terminus (Filppula 1998), and it has also been shown 
that the first 40 amino acids in the N terminus resembles a cleavable mitochondrial 
targeting signal as predicted by Mitoprot II analysis (Claros & Vincens 1996).  While 
mitochondrial fatty acidmetabolism is a major contributor to energy production and 
balance, peroxisomal fatty acid oxidation is only capable of shortening the fatty acyl-
CoA chains, while the complete degradation of the fatty acyl-CoA chain to generate ATP 
occurs exclusively in the mitochondria (Borgne & Demarquoy 2012).  Therefore, our 
finding that ECH1 localizes primarily to the mitochondria rather than peroxisomes is 
consistent with previous studies that ECH1 is important in maintaining pools of 
coenzyme A and regulating energy balance.  
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It has been proposed that ECH1 plays an important role in the disposal of 
unmetabolizable fatty acid metabolites (Shoukry & Schulz 1998). ECH1 is an essential 
auxiliary enzyme in the reductase-dependent pathway that is responsible for catalyzing 
the isomerization of the 3,5-dienoyl-CoA substrate to 2,4-dienoyl-CoA. This is regarded 
as a crucial step in the reductase-dependent pathway because unlike other fatty acid-
intermediates that can be metabolized by redundant fatty acid enzymes, the 3,5-dienoyl-
CoA substrate is a “dead end metabolite” that is exclusively metabolized by ECH1. 
Based on these realizations it was later suggested that the reductase-dependent pathway 
be renamed to the ECH1-dependent pathway (Shoukry & Schulz 1998) given that in the 
absence of ECH1 activity, the “dead end metabolite” would accumulate, sequester 
coenzyme A, and halt mitochondrial β-oxidation.       
Interestingly, the proposed physiological function of ECH1 is similar to previous 
theories by Harper et al. that suggest UCP3 also protects against lipotoxicity by 
facilitating fatty acid transport to maintain coenzyme A availability in conditions that 
require high levels of fatty acid oxidation.  In support of this notion, UCP3 expression is 
induced in response to high fat feeding and fasting, thus suggesting a role for UCP3 in 
conditions where the rates of mitochondrial fatty acid oxidation are high.  Furthermore, it 
has also been shown that UCP3 overexpression in SKM can lower circulating levels of 
acylcarnitines and thus facilitate complete fatty acid oxidation (Aguer et al. 2013). Based 
on these findings, it makes sense that UCP3 would interact with a fatty acid metabolizing 
enzyme to mediate efficient fatty acid oxidation.  Accordingly, our data demonstrating 
that ECH1:UCP3 complex formation is regulated through fatty acids and is likely 
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activated in conditions that require enhanced levels of fatty acid oxidation e.g. high fat 
feeding, suggests these two proteins could be facilitating a compensatory response to 
metabolic fatty acid overload. Indeed, we propose a modified model by which UCP3 
functions to maintain coenzyme A availability in part through ECH1-dependent 
metabolism of unsaturated fatty acids.  The finding that UCP3 and ECH1 expression 
synergistically increases oleic acid oxidation suggests that UCP3 binding could enhance 
ECH1 activity and promote unsaturated fatty acid oxidation.  In addition to this, we also 
demonstrate that ECH1 and UCP3 expression synergistically enhances uncoupled 
respiration in C2C12 myocytes.  Taken together, it is tempting to speculate that complex 
formation between ECH1 and UCP3 functions to coordinate fatty acid oxidation and 
uncoupling activity in a compensatory pathway that is activated in situations that require 
enhanced levels of fatty acid oxidation.   
Despite the numerous debates regarding the thermogenic capabilities of UCP3 in 
SKM, results herein demonstrate the UCP3 is important in mediating an adaptive 
thermogenic response to cold temperatures, in a fasted state.  The assumption that UCP3 
is not a physiological thermogenic regulator stems from the finding that UCP3-/- mice are 
able to maintain core body temperature in response to cold.  However, the lack of a cold-
phenotype may be due to a compensatory process, but it does not necessarily exclude the 
possibility that UCP3 can contribute to whole-body thermogenesis through alternative 
mechanisms that may be crucial in different physiological contexts. Indeed, UCP3 has 
been shown to be a crucial molecular mediator of non-shivering thermogenesis in 
response pharmacological amphetamines (Mills et al. 2003), and thyroid hormone 
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(Flandin et al. 2009) which is arguably one of the most important  hormonal regulators of 
whole body thermogenesis and energy metabolism.  Indeed, observed changes in UCP3 
expression in certain physiological contexts where mitochondria rely predominantly on 
fatty acid metabolism, along with mechanistic studies in fasted mice, suggest that UCP3 
may be relevant in mediating an adaptive increase in fatty acid oxidation capacity in 
SKM (Seifert et al. 2008).  Given that fasting and cold exposure are both stimulators of 
fatty acid oxidation, it is likely that the absence of UCP3 diminishes efficient fatty acid 
handling in response to these metabolic stressors, thus diminishing optimal cold-induced 
thermogenesis in UCP3-/- in a fasted stated.   
Lastly, we demonstrate for the first time that unsaturated fatty acid metabolism 
through the reductase/ECH1-dependent pathway is essential for thermogenesis in 
conditions of severe metabolic stress.  The impaired thermogenic phenotype seen in the 
ECH1-/- mice in response to fasting is similar to previous studies with mice lacking 
dienoyl-CoA reductase, an auxiliary enzyme involved in the metabolism of all species of 
unsaturated fatty acids (odd- and even-numbered double bonds) (Miinalainen et al. 2009).  
Despite previous work indicating that the reductase/ECH1-dependent pathway 
contributes to a minor portion of mitochondrial β-oxidation of unsaturated fatty acids 
with odd-numbered double bonds (Shoukry & Schulz 1998), our work clearly shows that 
impairment of this metabolic pathway can have a significant effect on whole-body 
thermogenesis in fasted conditions. Taken together, this data shows that ECH1 is an 
essential regulator of cold-induced thermogenesis in a fasted state, through a mechanism 
that is mediated in part through UCP3-dependent activity in SKM.  
 
 94 
 The present study is the first to establish a molecular mechanism by which UCP3 
can facilitate fatty acid metabolism in SKM and combat lipid-induced toxicity through 
complex formation with the auxiliary unsaturated fatty acid metabolism enzyme ECH1. 
Our work demonstrating that the ECH1:UCP3 complex can synergistically increase 
unsaturated fatty oxidation and uncoupled respiration provides the foundation for 
developing new treatments to combat obesity and related metabolic diseases.  In our 
proposed model, we predict that complex formation between ECH1 and UCP3 is key in 
coordinating a compensatory pathway that increases SKM capacity for fatty acid 
oxidation by facilitating efficient mitochondrial fatty acid transport and metabolism in 
conditions of severe metabolic stress (Illustration 5.1).  This work lays the foundation for 
the development of new anti-obesity therapies that focus on restoring energy balance by 







Illustration 5.1 Proposed model of ECH1 and UCP3 complex formation in 
protecting against metabolic stress 
In physiological conditions where fatty acid metabolism is elevated, ECH1:UCP3 
complex formation protects mitochondrial function by coordinating an increase in fatty 
acid oxidation and uncoupled respiration.  The thermogenic effects of UCP3 on proton 
conductance and mitochondrial respiration allows the electron transport chain to handle 
the excess supply of reduced cofactors (NADH and FADH2) generated from the 
increased flux though β-oxidation.  This coordinated response protects against the 





Chapter 6: Concluding remarks and future directions 
 
Since its discovery, UCP3 has remained an attractive target in treatment of 
obesity and related metabolic disorders despite the controversy surrounding its 
physiological relevance and thermogenic capabilities. The early observation that UCP3 
knockout mice exhibit normal thermoregulatory responses to cold, led many to believe 
that unlike BAT UCP1, UCP3 does not regulate thermogenesis.  However, the lack of a 
“cold-induced” phenotype in UCP3-/- mice could be explained by compensatory pathways 
(most likely UCP1) that mask any UCP3-dependent effects.  In addition to this, it is also 
possible that UCP3 activity may be more important in other thermogenic responses.  
Indeed, previous work has shown that UCP3 knockout mice lack thermogenic responses 
to various pharmacological amphetamines (Mills et al. 2003; Sprague, Mallett, et al. 
2004).  Herein, our work further substantiates the thermogenic capabilities of SKM UCP3 
in sympathomimetic-induced hyperthermia, and also demonstrates that activation of 
UCP3-dependent thermogenesis is particularly important conditions of severe metabolic 
stress (e.g. prolonged periods of fasting). The thermogenic effects of UCP3 are likely 
mediated in part through the identified interactions with key metabolic enzymes involved 
fatty acid metabolism (particularly ECH1), and efficient substrate selection in certain 
physiological contexts. Future studies that focus on further characterizing how these 
UCP3-regulated protein complexes can influence mitochondrial substrate preference and 





An attractive area of research that has gained momentum in recent years deals 
with the interplay between thermogenesis in BAT and SKM.  Although it was originally 
postulated that the role of SKM in regulating core body temperature was limited to 
shivering thermogenesis, it is now clear that SKM also possesses mechanisms of non-
shivering thermogenesis that greatly contribute to thermoregulation and energy balance 
(Kozak & Young 2012).  Interestingly, BAT and SKM originate from the same 
progenitor cells that diverge along separate lineages to give rise to either myoblasts or 
brown adipocytes (Seale et al. 2008).  Indeed, certain brown adipocyte “like” cells that 
correlate with increased energy expenditure have actually been identified in SKM tissue 
(Almind et al. 2007).  Although, the function of these specialized brown adipocytes 
requires additional investigation, it has been suggested that these cells might function to 
increase the oxidative capacity of SKM (Farmer 2008).      
Given the similar origins and metabolic features of BAT and SKM, it has been 
proposed that these distinct organs could have an interrelated role in regulating whole-
body thermogenesis. The idea that crosstalk between BAT and SKM exists, and plays a 
significant role in contributing to whole body thermogenesis is further supported by the 
observation that secretion of irisin and natriuretic peptide from SKM influences whole 
body thermogenesis by inducing brown adipocyte depots that are intersperse among 
white adipose tissue (Lee et al. 2014; Kozak & Young 2012).   Our data not only supports 
the possibility of interplay between these two distinct organs, but also suggest a new 
mechanism of crosstalk between BAT and SKM that is mediated through UCP1 and 
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UCP3.  Given that various stimulants of thermogenesis activate BAT and SKM to 
different extents in humans (Cypess et al. 2012; Astrup et al. 1984; Astrup et al. 1985) 
understanding the underlying mechanisms that regulate the relative contribution of the 
these two organs in whole body thermogenesis can be useful developing new treatments 
for obesity. 
With regard to the role of UCP3 in fatty acid metabolism, to our knowledge we 
are the first to show a detailed mechanism by which UCP3 influences fatty acid oxidation 
through its interaction with ECH1.  Furthermore, our work argues that complex formation 
between ECH1 and UCP3 opposes obesity-induced metabolic derangements in SKM by 
coordinating changes in fatty acid metabolism and energy demand.  Related studies with 
animals that specifically overexpress peroxisome proliferator-activated receptor-α 
(PPARα) in SKM support this view.  Even though these mice exhibited a higher rates of 
fatty acid oxidation due to PPAR-α overexpression, these mice were surprisingly more 
susceptible to diet-induced insulin resistance (Finck et al. 2005).  However, in the same 
study, the repressive effects of PPAR-α on glucose uptake were completely reversed in 
when L6 myotubes were treated with the chemical uncoupler DNP (Finck et al. 2005). 
These studies highlight the importance developing new obesity treatments that center on 
coordinating alterations in fatty acid metabolism with mitochondrial bioenergetics.   
A key feature in understanding mitochondrial bioenergetics is that all metabolic 
processes are interconnected and stimulating fuel oxidation, as a means to relieve nutrient 
overload, without increasing energy utilization will further exacerbate energy 
homeostasis. Therefore, normal mitochondrial bioenergetics requires coordination 
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between mitochondrial transporters, enzymes involved substrate catabolism (β-oxidation, 
TCA cycle, glycolysis), and the ETC.  It has been proposed that all these metabolic 
proteins and enzymes can function as monomeric units, or be arranged in large multi-
enzyme complexes that are capable of efficient substrate channeling (Goetzman 2011).  
Formation of these organized multi-enzyme complexes could play a role in regulating 
enzyme activity and would provide a clear kinetic advantage especially in conditions 
where flux through certain pathways is extremely high.  The data shown here is 
consistent with the growing literature that supports the importance of UCP3 activity in 
conditions where fatty acid oxidation levels are elevated.  In addition to its interactions 
with key enzymes involved in fatty acid metabolism (CPT1, ECHs1, Acat1, Acadm), 
UCP3 could possibly influence energy metabolism through its interaction with malate 
dehydrogenase 2 (MDH2) and other TCA cycle enzymes.  MDH2 is involved in the 
malate-aspartate shuttle that is responsible for the transport of reducing equivalents from 
cytosol to the mitochondria (LaNoue & Tischler 1974; LaNoue & Schoolwerth 1979).  
This shuttle system can also function in reverse and export NADH from mitochondria 
(Safer 1975) in situations where fatty acid supply and β-oxidation generation of NADH 
exceeds the energy demand  (e.g. fasting).  Thus, coordination between UCP3 and MDH2 
could function to prevent inhibition of oxidative phosphorylation by alleviating the 
intramitochondrial accumulation of NADH when fatty acid oxidation is high.  Future 
investigations to understand how formation of these UCP3 complexes are affected by 
changes in diet or nutritional status will reveal useful information of the underlying 
mechanisms of UCP3-dependent thermogenesis. 
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Another possibility that has yet to be investigated is the role of UCP3 in 
regulating cross talk between glucose and fatty acid metabolism.  It is likely that this 
would be particularly important in conditions that require efficient substrate switching i.e. 
metabolic flexibility.  The Randle cycle suggests that glucose and fatty acid metabolism 
oppose each other (Randle et al. 1963).  Therefore, in a fasted stated where fatty acids are 
the primary fuel substrate acetyl-CoA produced from β-oxidation will inhibit PDH 
activity and glycolysis.  However, when re-feeding begins insulin stimulated glucose 
uptake and catabolism leads to a surge in TCA cycle flux that is caused by acetyl-CoA 
generated from glycolysis and fatty acid metabolism.  This action results in mitochondrial 
efflux of the TCA cycle intermediate citrate and ultimately inhibits fatty acid uptake and 
oxidation through the malonyl-CoA / CPT1 axis.   
The counter regulatory actions between glucose and fatty acid metabolism are 
important in preventing the excessive generation of reducing equivalents produced from 
different catabolic substrates being fluxed into the same energetic pathways (TCA and 
ETC cycle).  The effectiveness of the Randle cycle centers on the allosteric inhibition of 
PDH and CPT1.  Interestingly, mechanisms that ease inhibition of PDH and facilitate a 
more rapid transition from fatty acid to glucose metabolism can improve overall 
mitochondrial bioenergetics (Muoio et al. 2012).  Our data supports a possible 
mechanism by which UCP3 influences insulin sensitivity and glucose homeostasis is by 
facilitating efficient substrate selection through its interaction with PDH and CPT1.  
Taken together, the work herein provides novel mechanistic information 
regarding how UCP3 influences SKM thermogenesis and bioenergetics through its broad 
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interactions with key enzymes involved in interconnected pathways of metabolism.  
Although numerous studies have suggested a fascinating link between defects in fatty 
acid metabolism and obesity-induced resistance, complications seen with obesity-induced 
insulin resistance are now recognized as disorders of metabolic flexibility.  In these 
conditions, nutrient overload increases substrate competition to a point where clear 
metabolic signaling between substrate catabolism and energy utilization is compromised.  
This action can have complex, detrimental effects on mitochondrial function and insulin 
signaling in SKM.  Our interaction and mechanistic studies suggest that UCP3 can 
counteract the effects of metabolic inflexibility by coordinating an increase in fatty acid 
oxidation and energy demand through its thermogenic actions. The work shown here also 
raises intriguing questions as to the direct effects that UCP3 may have on maintaining 
glucose homeostasis through complex formation with key enzymes involved in various 
catabolic pathways.  Ultimately, the diverse effects of UCP3 in SKM encompass diverse 
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